Diagnosing the decline in pharmaceutical R&D eff

Nature Reviews Drug Discovery
11, 191-200
DOI: 10.1038/nrd3681

Citation Report

#	Article	IF	Citations
1	ecancermedicalscience. Ecancermedicalscience, 2014, 8, 442.	0.6	122
2	Challenges in sexual medicine. Nature Reviews Urology, 2012, 9, 537-542.	1.9	8
3	AACR Cancer Progress Report 2012. Clinical Cancer Research, 2012, 18, S1-S100.	3.2	28
4	MALDI imaging MS analysis of drug distribution in tissue: the right time!(?). Bioanalysis, 2012, 4, 2549-2551.	0.6	24
5	Improving success of novel therapeutics for cognitive aspects of psychiatric disease: a bridge too far?. Expert Review of Clinical Pharmacology, 2012, 5, 601-603.	1.3	0
6	Systems drug discovery: a quantitative, objective approach for safer drug development. Expert Opinion on Drug Discovery, 2012, 7, 757-759.	2.5	5
7	Productive university, industry, and government relationships in preclinical drug discovery and development: considerations toward a synergisticlingua franca. Expert Opinion on Drug Discovery, 2012, 7, 449-456.	2.5	12
8	Novel Stem Cellâ€"Based Drug Discovery Platforms for Cardiovascular Disease. Journal of Biomolecular Screening, 2012, 17, 1117-1127.	2.6	5
9	The Challenges in Implementing Open Innovation in a Global Innovation-Driven Corporation. Research Technology Management, 2012, 55, 32-38.	0.6	33
10	The penumbra of thalidomide, the litigation culture and the licensing of pharmaceuticals. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 1179-1189.	0.2	16
13	Translational Success Stories. Circulation Research, 2012, 111, 920-929.	2.0	61
14	Future directions in phosphodiesterase drug discovery. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6794-6800.	1.0	28
15	Reconsidering phenotypic heart failure drug discovery. Drug Discovery Today: Therapeutic Strategies, 2012, 9, e199-e203.	0.5	0
16	The 6th Drug Discovery for Neurodegeneration Conference: An Intensive Course on Translating Research into Drugs. Expert Opinion on Drug Discovery, 2012, 7, 1225-1228.	2.5	1
17	Value for money of drug regulation. Expert Review of Pharmacoeconomics and Outcomes Research, 2012, 12, 247-249.	0.7	4
18	Knowledge Engineering and Knowledge Management. Lecture Notes in Computer Science, 2012, , .	1.0	3
19	Induced pluripotent stem cells: the new patient?. Nature Reviews Molecular Cell Biology, 2012, 13, 713-726.	16.1	377
20	Translational medicine as a permanent glue and force of clinical medicine and public health: perspectives (1) from 2012 Sinoâ€American symposium on clinical and translational medicine. Clinical and Translational Medicine, 2012, 1, 21.	1.7	7

#	Article	IF	Citations
21	Biosimilars: Company Strategies to Capture Value from the Biologics Market. Pharmaceuticals, 2012, 5, 1393-1408.	1.7	64
22	Shaping a Screening File for Maximal Lead Discovery Efficiency and Effectiveness: Elimination of Molecular Redundancy. Journal of Chemical Information and Modeling, 2012, 52, 2937-2949.	2.5	36
23	What is the most important approach in current drug discovery: doing the right things or doing things right?. Drug Discovery Today, 2012, 17, 1166-1169.	3.2	21
25	Four Lessons from Global Health Drug Discovery: Medicine for an Ailing Industry?. ACS Medicinal Chemistry Letters, 2012, 3, 688-690.	1.3	12
26	Microengineered physiological biomimicry: Organs-on-Chips. Lab on A Chip, 2012, 12, 2156.	3.1	584
27	Validating therapeutic targets through human genetics. Nature Reviews Drug Discovery, 2013, 12, 581-594.	21.5	548
28	Combinatorial Biomatrix/Cellâ€Based Therapies for Restoration of Host Tissue Architecture and Function. Advanced Healthcare Materials, 2013, 2, 1544-1563.	3.9	13
29	White Paper: Landscape on Technical and Conceptual Requirements and Competence Framework in Drug/Disease Modeling and Simulation. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-8.	1.3	15
30	Allosteric transition: a comparison of two models. BMC Pharmacology & Toxicology, 2013, 14, 4.	1.0	5
31	New developments in parenteral anticoagulation for arterial and venous thromboembolism. Best Practice and Research in Clinical Haematology, 2013, 26, 203-213.	0.7	8
32	Bibliometrics evaluation of research performance in pharmacology/pharmacy: China relative to ten representative countries. Scientometrics, 2013, 96, 829-844.	1.6	29
33	Discontinued drugs in 2012: cardiovascular drugs. Expert Opinion on Investigational Drugs, 2013, 22, 1437-1451.	1.9	5
34	Lessons from (S)-6-(1-(6-(1-Methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats. Journal of Medicinal Chemistry, 2013, 56, 6651-6665.	2.9	26
35	Pathway-based drug repositioning using causal inference. BMC Bioinformatics, 2013, 14, S3.	1.2	71
36	Post-Approval Safety Issues with Innovative Drugs: A European Cohort Study. Drug Safety, 2013, 36, 1105-1115.	1.4	27
37	The Emergence of Regulatory Science in Pharmaceutical Medicine. Pharmaceutical Medicine, 2013, 27, 345-351.	1.0	11
38	Synthetic Macrocycles in Small-Molecule Drug Discovery. Annual Reports in Medicinal Chemistry, 2013, , 371-386.	0.5	17
39	Flow chemistry approaches directed at improving chemical synthesis. Green Processing and Synthesis, 2013, 2, .	1.3	24

#	Article	IF	Citations
40	Buying big into biotech: scale, financing, and the industrial dynamics of UK biotech, 1980-2009. Industrial and Corporate Change, 2013, 22, 903-952.	1.7	27
41	How can attrition rates be reduced in cancer drug discovery?. Expert Opinion on Drug Discovery, 2013, 8, 363-368.	2.5	97
42	The Cost-Effectiveness of Periodic Safety Update Reports for Biologicals in Europe. Clinical Pharmacology and Therapeutics, 2013, 93, 433-442.	2.3	14
43	A safe lithium mimetic for bipolar disorder. Nature Communications, 2013, 4, 1332.	5.8	221
44	Discontinued drugs in 2011: oncology drugs. Expert Opinion on Investigational Drugs, 2013, 22, 9-34.	1.9	18
45	An integrated strategy of ultra-high-performance liquid chromatography/quadrupole-time-of-flight mass spectrometry and virtual screening for the identification of l±-glucosidase inhibitors in acarviostatin-containing complex. Journal of Chromatography A, 2013, 1319, 88-96.	1.8	11
46	Expanding research to provide an evidence base for nutritional interventions for the management of inborn errors of metabolism. Molecular Genetics and Metabolism, 2013, 109, 319-328.	0.5	19
47	Approval probabilities and regulatory review patterns for anticancer drugs in the European Union. Critical Reviews in Oncology/Hematology, 2013, 87, 112-121.	2.0	34
48	Translational medicines research. Drug Discovery Today, 2013, 18, 503-505.	3.2	6
50	Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery. Journal of Pharmacological and Toxicological Methods, 2013, 67, 69-81.	0.3	35
52	The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives. Drug Discovery Today, 2013, 18, 853-862.	3.2	37
53	Modeling Human Disease with Pluripotent Stem Cells: from Genome Association to Function. Cell Stem Cell, 2013, 12, 656-668.	5.2	176
54	Understanding drugs and diseases by systems biology?. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 1168-1176.	1.0	25
55	Policy to support marine biotechnology-based solutions to global challenges. Trends in Biotechnology, 2013, 31, 128-131.	4.9	8
56	Structure and dynamics of molecular networks: A novel paradigm of drug discovery. , 2013, 138, 333-408.		779
57	The integration of flow reactors into synthetic organic chemistry. Journal of Chemical Technology and Biotechnology, 2013, 88, 519-552.	1.6	231
58	Industrial Applications of the Dielsâ€“Alder Reaction. Angewandte Chemie - International Edition, 2013, 52, 3822-3863.	7.2	229
59	Wandel und Herausforderung â€“ die pharmazeutische Industrie. , 2013, , 1-52.		0

#	Article	IF	Citations
60	Impact of preformulation on drug development. Expert Opinion on Drug Delivery, 2013, 10, 1239-1257.	2.4	37
61	Nanotheranostics for personalized medicine. Expert Review of Molecular Diagnostics, 2013, 13, 257-269.	1.5	178
62	Incorporation of Rapid Thermodynamic Data in Fragment-Based Drug Discovery. Journal of Medicinal Chemistry, 2013, 56, 2155-2159.	2.9	18
65	Plate-based diversity subset screening: an efficient paradigm for high throughput screening of a large screening file. Molecular Diversity, 2013, 17, 319-335.	2.1	7
66	Integrating Human Pluripotent Stem Cells into Drug Development. Cell Stem Cell, 2013, 12, 669-677.	5.2	123
67	Applying systems biology in drug discovery and development. Drug Metabolism and Drug Interactions, 2013, 28, 67-78.	0.3	10
68	Diversifying complexity. Nature Chemistry, 2013, 5, 157-158.	6.6	65
69	Artemisinin-derived dimer phosphate esters as potent anti-cytomegalovirus (anti-CMV) and anti-cancer agents: A structureâ€“activity study. Bioorganic and Medicinal Chemistry, 2013, 21, 3702-3707.	1.4	33
70	Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment. Lab on A Chip, 2013, 13, 229-239.	3.1	126
71	Neural stem cells as tools for drug discovery: novel platforms and approaches. Expert Opinion on Drug Discovery, 2013, 8, 1083-1094.	2.5	19
72	Physicochemical and DMPK In Silico Models: Facilitating Their Use by Medicinal Chemists. Molecular Pharmaceutics, 2013, 10, 1153-1161.	2.3	20
73	Clinical Pharmacology and the Catalysis of Regulatory Science: Opportunities for the Advancement of Drug Development and Evaluation. Clinical Pharmacology and Therapeutics, 2013, 93, 515-525.	2.3	34
74	Chemical Biology Consortium Sweden. ACS Chemical Biology, 2013, 8, 2605-2606.	1.6	7
75	Impact of biomarkers on clinical trial risk. Pharmacogenomics, 2013, 14, 1645-1658.	0.6	6
76	Decline in new drug launches: myth or reality? Retrospective observational study using 30â€…years of data from the UK. BMJ Open, 2013, 3, e002088.	0.8	19
77	Pressure-Driven Microfluidic Perfusion Culture Device for Integrated Dose-Response Assays. Journal of the Association for Laboratory Automation, 2013, 18, 437-445.	2.8	6
78	Use of Multiple Endpoints and Approval Paths Depicts a Decade of FDA Oncology Drug Approvals. Clinical Cancer Research, 2013, 19, 3722-3731.	3.2	26
79	Financialization and productive models in the pharmaceutical industry. Industrial and Corporate Change, 2013, 22, 981-1030.	1.7	57

#	Article	IF	Citations
80	Patient-Specific Stem Cells and Cardiovascular Drug Discovery. JAMA - Journal of the American Medical Association, 2013, 310, 2039.	3.8	33
81	Challenges in the design of multitarget drugs against multifactorial pathologies: a new life for medicinal chemistry?. Future Medicinal Chemistry, 2013, 5, 5-7.	1.1	22
82	Developing doctoral scientists for drug discovery: pluridimensional education required. Expert Opinion on Drug Discovery, 2013, 8, 105-113.	2.5	7
83	VinaMPI: Facilitating multiple receptor high-throughput virtual docking on high-performance computers. Journal of Computational Chemistry, 2013, 34, 2212-2221.	1.5	62
84	Developability assessment as an early de-risking tool for biopharmaceutical development. Pharmaceutical Bioprocessing, 2013, 1, 29-50.	0.8	51
85	General Introduction on Pharmaceuticals. Comprehensive Analytical Chemistry, 2013, , 1-36.	0.7	2
86	Clinical studies in lysosomal storage diseases. Rare Diseases (Austin, Tex), 2013, 1, e26690.	1.8	7
87	Â¿QuÃ© aportan los nuevos fÃ¡rmacos antiepilÃ©pticos?. Revista MÃ©dica ClÃnica Las Condes, 2013, 24, 995-1003.	0.2	0
88	Poly(DL-lactide-co-glycolic acid) Nanoparticle Design and Payload Prediction: A Molecular Descriptor Based Study. Chemical and Pharmaceutical Bulletin, 2013, 61, 125-133.	0.6	5
91	Gatekeepers and Enablers: How Drug Regulators Respond to a Challenging and Changing Environment by Moving Toward a Proactive Attitude. Clinical Pharmacology and Therapeutics, 2013, 93, 425-432.	2.3	33
92	An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles. Beilstein Journal of Organic Chemistry, 2013, 9, 2265-2319.	1.3	642
93	Using Network Biology to Bridge Pharmacokinetics and Pharmacodynamics in Oncology. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-7.	1.3	27
94	Drugs for solid cancer the productivity crisis prompts a rethink. OncoTargets and Therapy, 2013, 6, 767.	1.0	9
95	Stock Market Returns and Clinical Trial Results of Investigational Compounds: An Event Study Analysis of Large Biopharmaceutical Companies. PLoS ONE, 2013, 8, e71966.	1.1	23
96	Metal Species in Biology: Bottom-Up and Top-Down LC Approaches in Applied Toxicological Research. ISRN Chromatography, 2013, 2013, 1-21.	0.6	7
97	Colon Cancer: Current Treatments and Preclinical Models for the Discovery and Development of New Therapies. , 2013, , .		5
98	Label-free drug discovery. Frontiers in Pharmacology, 2014, 5, 52.	1.6	66
99	Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles. Current Pharmaceutical Design, 2014, 20, 23-36.	0.9	115

#	Article	IF	Citations
100	Synthesis of Riboflavines, Quinoxalinones and Benzodiazepines through Chemoselective Flow Based Hydrogenations. Molecules, 2014, 19, 9736-9759.	1.7	26
101	Comparative Employment Systems. , 2014, , .		5
102	Drug Design and Development: A Research Center More Than Twenty Years in the Making. Chemistry International, 2014, 36, .	0.3	1
106	Opening the door to innovation. MAbs, 2014, 6, 812-819.	2.6	14
107	A high efficiency, high quality and low cost internal regulated bioanalytical laboratory to support drug development needs. Bioanalysis, 2014, 6, 1295-1309.	0.6	4
108	Cone snail venomics: from novel biology to novel therapeutics. Future Medicinal Chemistry, 2014, 6, 1659-1675.	1.1	72
109	Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivity. Nature Reviews Drug Discovery, 2014, 13, 638-640.	21.5	13
110	How to integrate biological research into society and exclude errors in biomedical publications? Progress in theoretical and systems biology releases pressure on experimental research. Communicative and Integrative Biology, 2014, 7, e27966.	0.6	1
111	Pharmaceutical regulation in Europe and its impact on corporate R&D. Health Economics Review, 2014, 4, 23.	0.8	23
112	Data Donation Could Power the Learning Health Care System, Including Special Access Programs. American Journal of Bioethics, 2014, 14, 27-29.	0.5	8
113	Self-Microemulsifying Materials. , 2014, , 117-176.		0
114	Regenerative Medicine: Transforming the Drug Discovery and Development Paradigm. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a014084-a014084.	2.9	9
116	Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development. Frontiers in Pharmacology, 2014, 5, 247.	1.6	57
117	The battle of AlzheimerÃ¢â‚¬â„¢s Disease Ã¢â‚¬Å“ the beginning of the future Unleashing the potential of academic discoveries. Frontiers in Pharmacology, 2014, 5, 102.	1.6	18
118	Innovation in Therapeutics Development at the NCATS. Neuropsychopharmacology, 2014, 39, 230-232.	2.8	13
119	Knowledge-based Fragment Binding Prediction. PLoS Computational Biology, 2014, 10, e1003589.	1.5	32
120	The value of translational biomarkers to phenotypic assays. Frontiers in Pharmacology, 2014, 5, 171.	1.6	19
121	Production of Drug-Loaded Polymeric Nanoparticles by Electrospraying Technology. Journal of Biomedical Nanotechnology, 2014, 10, 2200-2217.	0.5	34

#	Article	IF	Citations
122	We need a global system to help identify new uses for existing drugs. BMJ, The, 2014, 348, g1806-g1806.	3.0	3
123	Beyond the pill: The move towards value-added services in the pharmaceutical industry. Journal of Medical Marketing, 2014, 14, 91-98.	0.2	7
124	Improving productivity of modern-day drug discovery. Expert Opinion on Drug Discovery, 2014, 9, 115-118.	2.5	10
125	The biggest challenges currently facing companion diagnostic advancement. Expert Review of Molecular Diagnostics, 2014, 14, 27-35.	1.5	5
126	Chemistry at the Core of Biomedical Innovation. ACS Symposium Series, 2014, , 25-31.	0.5	0
127	To screen or not to screen: an impassioned plea for smarter chemical libraries to improve drug lead finding. Future Medicinal Chemistry, 2014, 6, 497-502.	1.1	4
128	Potential strategies for increasing drug-discovery productivity. Future Medicinal Chemistry, 2014, 6, 515-527.	1.1	18
129	The Shifting Currents of Bioscience Innovation. Global Policy, 2014, 5, 76-84.	1.0	3
130	Systematic, spatial imaging of large multimolecular assemblies and the emerging principles of supramolecular order in biological systems. Journal of Molecular Recognition, 2014, 27, 3-18.	1.1	22
131	Drug Delivery. , 2014, , .		22
132	Efficient Engineering and Production Concepts for Products in Regulated Environments â€“ Dream or Nightmare?. Chemie-Ingenieur-Technik, 2014, 86, 687-694.	0.4	12
133	Drug Discovery Alliances in India-Indications, Targets, and New Chemical Entities. ChemMedChem, 2014, 9, 43-60.	1.6	5
134	Novel Statistical Designs for Phase I/II and Phase II Clinical Trials With Dose-Finding Objectives. Therapeutic Innovation and Regulatory Science, 2014, 48, 601-612.	0.8	6
135	Research and development productivity map: visualization of industry status. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 175-180.	0.7	14
136	Chapter 11. Human Microdosing/PhaseÂ0 Studies to Accelerate Drug Development. RSC Drug Discovery Series, 2014, , 241-266.	0.2	0
137	Alcohol Medications Development: Advantages and Caveats of Government/Academia Collaborating with the Pharmaceutical Industry. Alcoholism: Clinical and Experimental Research, 2014, 38, 1196-1199.	1.4	9
138	Evolving Global Regulatory Science Through the Voluntary Submission of Data: A 2013 Assessment. Therapeutic Innovation and Regulatory Science, 2014, 48, 236-245.	0.8	5
139	Pharmaceutical R&D Performance by Firm Size. American Journal of Therapeutics, 2014, 21, 26-34.	0.5	26

#	Article	IF	Citations
140	Advances in the treatment of aortic valve disease. Current Opinion in Pediatrics, 2014, 26, 546-552.	1.0	5
141	Demonstrating Enhanced Throughput of RapidFire Mass Spectrometry through Multiplexing Using the JmjD2d Demethylase as a Model System. Journal of Biomolecular Screening, 2014, 19, 278-286.	2.6	41
142	Vascularizing engineered tissues for in vivo and in vitro applications. , 2014, , 283-298.		1
143	A lesson from Japan: Research and development efficiency is a key element of pharmaceutical industry consolidation process. Drug Discoveries and Therapeutics, 2014, 8, 57-63.	0.6	8
144	Science in Two Minds: Reflections on the Missional Disunity Within Contemporary Medicine. Christian Bioethics, 2014, 20, 359-375.	0.1	1
145	Asymptomatic Carotid Artery Stenosis Treated with Medical Therapy Alone: Temporal Trends and Implications for Risk Assessment and the Design of Future Studies. Cerebrovascular Diseases, 2014, 38, 163-173.	0.8	57
146	Synthetic Biology: Solving the Pharmaceutical Industryâ€™s Innovation Problems?. , 2014, , 11-18.		2
147	Patient representatives' contributions to the benefit-risk assessment tasks of the European Medicines Agency scientific committees. British Journal of Clinical Pharmacology, 2014, 78, 1248-1256.	1.1	7
148	Medical Innovation Then and Now: Perspectives of Innovators Responsible for Transformative Drugs. Journal of Law, Medicine and Ethics, 2014, 42, 564-575.	0.4	9
149	The fall and rise of pharmacology â€“ (Re-)defining the discipline?. Biochemical Pharmacology, 2014, 87, 4-24.	2.0	28
150	Macrocyclic Drugs and Clinical Candidates: What Can Medicinal Chemists Learn from Their Properties?. Journal of Medicinal Chemistry, 2014, 57, 278-295.	2.9	458
151	Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery. Drug Discovery Today, 2014, 19, 171-182.	3.2	140
152	Toxicogenomics â€“ A Drug Development Perspective. , 2014, , 127-155.		0
153	Discovery of Innovative Therapeutics: Todayâ€™s Realities and Tomorrowâ€™s Vision. 2. Pharmaâ€™s Challenges and Their Commitment to Innovation. Journal of Medicinal Chemistry, 2014, 57, 5525-5553.	2.9	43
154	New Financial and Research Models for Pediatric Orphan Drug Development: Focus on the NCATS TRND Program. Pharmaceutical Medicine, 2014, 28, 1-6.	1.0	3
155	Accessing New Chemical Entities through Microfluidic Systems. Angewandte Chemie - International Edition, 2014, 53, 5750-5758.	7.2	86
156	Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nature Reviews Drug Discovery, 2014, 13, 419-431.	21.5	1,067
157	Systems biology, complexity, and the impact on antiepileptic drug discovery. Epilepsy and Behavior, 2014, 38, 131-142.	0.9	34

#	Article	IF	Citations
158	LIBSA â€“ A Method for the Determination of Ligand-Binding Preference to Allosteric Sites on Receptor Ensembles. Journal of Chemical Information and Modeling, 2014, 54, 530-538.	2.5	14
159	Translational paradigms in pharmacology and drug discovery. Biochemical Pharmacology, 2014, 87, 189-210.	2.0	31
160	Multifaceted Roles of Disulfide Bonds. Peptides as Therapeutics. Chemical Reviews, 2014, 114, 901-926.	23.0	477
161	A systematic study of chemogenomics of carbohydrates. Molecular BioSystems, 2014, 10, 391-397.	2.9	9
162	Organs on microfluidic chips: A mini review. Science China Chemistry, 2014, 57, 356-364.	4.2	33
163	Replicated, replicable and relevantâ€“target engagement and pharmacological experimentation in the 21st century. Biochemical Pharmacology, 2014, 87, 64-77.	2.0	28
164	Modeling human carcinomas: Physiologically relevant 3D models to improve anti-cancer drug development. Advanced Drug Delivery Reviews, 2014, 79-80, 50-67.	6.6	129
165	Drug discovery goes back to school: changing ecosystem of drug discovery and the rising role of academia. Journal of the Peripheral Nervous System, 2014, 19, S2-4.	1.4	3
166	Therapeutic Drug Development and Human Clinical Trials. , 2014, , 315-330.		1
167	RISING R&D INTENSITY AND ECONOMIC GROWTH. Economic Inquiry, 2014, 52, 1427-1445.	1.0	2
168	Development of Antiâ€inflammatory Drugs â€“ the Research and Development Process. Basic and Clinical Pharmacology and Toxicology, 2014, 114, 7-12.	1.2	15
169	Toxins and drug discovery. Toxicon, 2014, 92, 193-200.	0.8	156
170	Lead Discovery and Lead Modification. , 2014, , 19-122.		7
171	Control of the Morphology of Lipid Layers by Substrate Surface Chemistry. Langmuir, 2014, 30, 2799-2809.	1.6	29
172	Employing a dual polarisation microring to determine refractive index and thickness of a thin polymer layer. , 2014, , .		0
173	Whole-Animal Chemical Screen Identifies Colistin as a New Immunomodulator That Targets Conserved Pathways. MBio, 2014, 5, .	1.8	34
175	Biological Networks and Drug Discoveryâ€”Where Do We Stand?. Drug Development Research, 2014, 75, 271-282.	1.4	12
176	The Current State of Drug Discovery and a Potential Role for NMR Metabolomics. Journal of Medicinal Chemistry, 2014, 57, 5860-5870.	2.9	52

#	Article	IF	Citations
177	Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates. Chemistry and Biology, 2014, 21, 1115-1142.	6.2	523
178	CANDO and the infinite drug discovery frontier. Drug Discovery Today, 2014, 19, 1353-1363.	3.2	67
179	Combining Metabolic Pathway Design and Retrosynthetic Planning for the Design of a Novel Semisynthetic Manufacturing Scheme for Paclitaxel. Organic Process Research and Development, 2014, 18, 816-826.	1.3	4
180	The discovery of first-in-class drugs: origins and evolution. Nature Reviews Drug Discovery, 2014, 13, 577-587.	21.5	412
181	Phenotypic screening in cancer drug discovery â€" past, present and future. Nature Reviews Drug Discovery, 2014, 13, 588-602.	21.5	403
182	Phage therapyâ€"constraints and possibilities. Upsala Journal of Medical Sciences, 2014, 119, 192-198.	0.4	153
183	Can stem-cell-derived models revolutionize drug discovery?. Expert Opinion on Drug Discovery, 2014, 9, 9-13.	2.5	6
184	A new and improved method for the preparation of drug nanosuspension formulations using acoustic mixing technology. International Journal of Pharmaceutics, 2014, 473, 10-19.	2.6	42
185	Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment. Nature Medicine, 2014, 20, 591-593.	15.2	95
186	Despite High Costs, Specialty Drugs May Offer Value For Money Comparable To That Of Traditional Drugs. Health Affairs, 2014, 33, 1751-1760.	2.5	22
187	Small Molecule Screening in Human Induced Pluripotent Stem Cell-derived Terminal Cell Types. Journal of Biological Chemistry, 2014, 289, 4562-4570.	1.6	37
188	Overcoming Drug Development Bottlenecks With Repurposing: Old drugs learn new tricks. Nature Medicine, 2014, 20, 590-591.	15.2	169
189	Restructuring and innovation in pharmaceuticals and biotechs: The impact of financialisation. Critical Perspectives on Accounting, 2014, 25, 67-77.	2.7	30
190	Determining Physical Principles of Subcellular Organization. Developmental Cell, 2014, 29, 135-138.	3.1	14
191	Drug development and discovery: challenges and opportunities. Drug Discovery Today, 2014, 19, 1679-1681.	3.2	8
192	AMPK-derived peptides reduce blood glucose levels but lead to fat retention in the liver of obese mice. Journal of Endocrinology, 2014, 221, 89-99.	1.2	5
193	The development speed paradox: can increasing development speed reduce R&D productivity?. Drug Discovery Today, 2014, 19, 209-214.	3.2	8
194	Surveying Recent Themes in Translational Bioinformatics: Big Data in EHRs, Omics for Drugs, and Personal Genomics. Yearbook of Medical Informatics, 2014, 23, 199-205.	0.8	18

#	Article	IF	Citations
197	Transforming Biopharma Innovation via Global Collaboration. ACS Symposium Series, 2014, , 183-189.	0.5	0
198	Evidence-Based Medicine as a Tool for Undergraduate Probability and Statistics Education. CBE Life Sciences Education, 2015, 14, ar42.	1.1	8
202	Improving Access to Medicines in Lowâ€Income Countries: A Review of Mechanisms. Journal of World Intellectual Property, 2015, 18, 1-28.	0.2	6
203	Biopharmaceutical Informatics: Applications of Computation in Biologic Drug Development. , 2015, , 3-34.		3
204	Taking Advantage of Emergence. , 2015, , 157-179.		4
206	Are medical breakthroughs declining â€“ The importance of case reports?. Indian Heart Journal, 2015, 67, S1-S3.	0.2	4
207	Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981-2014: a retrospective observational study. BMJ Open, 2015, 5, e009333-e009333.	0.8	10
208	Are scientists a workforce? â€“ Or, how Dr. Frankenstein made biomedical research sick. EMBO Reports, 2015, 16, 1592-1600.	2.0	14
209	Big biomedical data and cardiovascular disease research: opportunities and challenges. European Heart Journal Quality of Care & Clinical Outcomes, 2015, 1, 9-16.	1.8	48
211	Some imminent but overlooked preanalytical and analytical challenges currently facing biomarkers and companion diagnostics. Annals of the New York Academy of Sciences, 2015, 1346, 63-70.	1.8	8
212	Future technology insight: mass spectrometry imaging as a tool in drug research and development. British Journal of Pharmacology, 2015, 172, 3266-3283.	2.7	55
213	Use of the conditional marketing authorization pathway for oncology medicines in Europe. Clinical Pharmacology and Therapeutics, 2015, 98, 534-541.	2.3	49
214	Skin cancer, and some limitations on how we innovate andÂpractice medicine. British Journal of Dermatology, 2015, 173, 547-551.	1.4	0
215	Financial Returns on R&D: Looking Back at History, Looking Forward to Adaptive Licensing. Reviews on Recent Clinical Trials, 2015, 10, 28-43.	0.4	8
216	Advanced Human In vitro Models for the Discovery and Development of Lung Cancer Therapies. , 2015, , .		3
217	Lessons from Toxicology: Developing a 21st-Century Paradigm for Medical Research. Environmental Health Perspectives, 2015, 123, A268-72.	2.8	57
218	Microfluidic Organ/Body-on-a-Chip Devices at the Convergence of Biology and Microengineering. Sensors, 2015, 15, 31142-31170.	2.1	124
219	Î¼Organo: A LegoÂ®-Like Plug & Play System for Modular Multi-Organ-Chips. PLoS ONE, 2015, 10, e0139587.	1.1	94

#	Article	IF	Citations
220	Identifying problematic drugs based on the characteristics of their targets. Frontiers in Pharmacology, 2015, 6, 186.	1.6	11
221	Reverse Innovation and Reverse Technology Transfer: From Made in China to Discovered in China in the Pharmaceutical Sector. Management International, 2015, 19, 49-69.	0.1	10
223	Copy Number Networks to Guide Combinatorial Therapy of Cancer and Proliferative Disorders. , 2015, , 389-407.		2
225	Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. Molecular Psychiatry, 2015, 20, 820-826.	4.1	89
226	The Life Sciences Translational Challenge: The European Perspective. Therapeutic Innovation and Regulatory Science, 2015, 49, 415-424.	0.8	2
227	Creating Patient-Specific Neural Cells for the InÂVitro Study of Brain Disorders. Stem Cell Reports, 2015, 5, 933-945.	2.3	72
228	Saving and Improving Lives in the Information Age. Circulation, 2015, 131, 2238-2242.	1.6	3
229	The in-silico lab-on-a-chip. , 2015, , .		14
230	Challenges in the Biomedical Research Enterprise in the 21st century: Antecedents in the writings of David Triggle. Biochemical Pharmacology, 2015, 98, 342-359.	2.0	6
231	Determination of thickness and density of a wet multilayer polymer system with sub-nanometer resolution by means of a dual polarization silicon-on-insulator microring. , 2015, , .		0
232	Repurposing and Rescuing of Mibefradil, an Antihypertensive, for Cancer: A Case Study. Assay and Drug Development Technologies, 2015, 13, 650-653.	0.6	21
233	Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease. Neurotherapeutics, 2015, 12, 132-142.	2.1	58
234	Using transcriptomics to guide lead optimization in drug discovery projects: Lessons learned from the QSTAR project. Drug Discovery Today, 2015, 20, 505-513.	3.2	80
235	Antitumour efficacy of the selumetinib and trametinib MEK inhibitors in a combined human airwayâ€“tumourâ€“stroma lung cancer model. Journal of Biotechnology, 2015, 205, 111-119.	1.9	23
236	Differentiation of small alkane and alkyl halide constitutional isomers via encapsulation. Organic and Biomolecular Chemistry, 2015, 13, 1869-1877.	1.5	10
237	Crowdsourcing in pharma: a strategic framework. Drug Discovery Today, 2015, 20, 874-883.	3.2	31
238	Improving Pharmaceutical Innovation By Building A More Comprehensive Database On Drug Development And Use. Health Affairs, 2015, 34, 319-327.	2.5	13
239	Guidelines for Translational Research in Heart Failure. Journal of Cardiovascular Translational Research, 2015, 8, 3-22.	1.1	28

#	Article	IF	Citations
240	Impact of source data verification on data quality in clinical trials: an empirical post hoc analysis of three phase 3 randomized clinical trials. British Journal of Clinical Pharmacology, 2015, 79, 660-668.	1.1	34
241	Addressing the Right Targets in Oncology. Journal of Biomolecular Screening, 2015, 20, 305-317.	2.6	14
242	Discontinued anxiolytic drugs (2009 â€“ 2014). Expert Opinion on Investigational Drugs, 2015, 24, 557-573.	1.9	8
243	Peptide therapeutics: Targeting the undruggable space. European Journal of Medicinal Chemistry, 2015, 94, 459-470.	2.6	267
244	The pain of pain: Challenges of animal behavior models. European Journal of Pharmacology, 2015, 753, 183-190.	1.7	27
245	The genome and transcriptome of the zoonotic hookworm Ancylostoma ceylanicum identify infection-specific gene families. Nature Genetics, 2015, 47, 416-422.	9.4	91
246	Operational Excellence in Practiceâ€"the Application of a Takt-Time Analysis in Pharmaceutical Manufacturing. Journal of Pharmaceutical Innovation, 2015, 10, 99-108.	1.1	7
247	What Are Current Main Obstacles to Reach Drug Approval?. , 2015, , 17-22.		0
248	Why Is the Pharmaceutical and Biotechnology Industry Struggling?. , 2015, , 3-15.		4
249	Propeller-shaped molecules with a thiazole hub: structural landscape and hydrazone cap mediated tunable host behavior in 4-hydrazino-1,3-thiazoles. CrystEngComm, 2015, 17, 5978-5986.	1.3	3
250	Molecular mechanism matters: Benefits of mechanistic computational models for drug development. Pharmacological Research, 2015, 99, 149-154.	3.1	30
251	Drug Targets, Target Identification, Validation, and Screening. , 2015, , 45-70.		2
252	An analysis of original research contributions toward FDA-approved drugs. Drug Discovery Today, 2015, 20, 1182-1187.	3.2	42
253	Developing predictive assays: The phenotypic screening â€œrule of 3â€. Science Translational Medicine, 2015, 7, 293ps15.	5.8	153
254	Cheminformatic comparison of approved drugs from natural product versus synthetic origins. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 4802-4807.	1.0	129
255	Elucidating Compound Mechanism of Action by Network Perturbation Analysis. Cell, 2015, 162, 441-451.	13.5	278
256	The Discovery Channel: microfluidics and microengineered systems in drug screening. Integrative Biology (United Kingdom), 2015, 7, 285-288.	0.6	5
257	Rchemcpp: a web service for structural analoging in ChEMBL, Drugbank and the Connectivity Map. Bioinformatics, 2015, 31, 3392-3394.	1.8	16

#	Article	IF	Citations
258	Do We Need a Science of Science?. , 2015, , 3-53.		0
259	BalestraWeb: efficient online evaluation of drugâ€“target interactions. Bioinformatics, 2015, 31, 131-133.	1.8	28
260	Accessing external innovation in drug discovery and development. Expert Opinion on Drug Discovery, 2015, 10, 579-589.	2.5	10
261	A history of drug development in four acts. Drug Discovery Today, 2015, 20, 1163-1168.	3.2	4
262	Improving the predictive value of interventional animal models data. Drug Discovery Today, 2015, 20, 475-482.	3.2	19
263	Repurposing and Rescuing of Mibefradil, an Antihypertensive, for Cancer: A Case Study. Drug Repurposing Rescue and Repositioning, 2015, 1, 36-39.	0.0	1
264	Effective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D). Trials, 2015, 16, 86.	0.7	9
265	Clinical Drug Development Using Dynamic Biomarkers to Enable Personalized Health Care in COPD. Chest, 2015, 148, 16-23.	0.4	22
266	Induced Pluripotent Stem Cell Models to Enable In Vitro Models for Screening in the Central Nervous System. Stem Cells and Development, 2015, 24, 1852-1864.	1.1	34
267	Racing to define pharmaceutical R&D external innovation models. Drug Discovery Today, 2015, 20, 361-370.	3.2	49
268	Influenza virus-induced lung injury: pathogenesis and implications for treatment. European Respiratory Journal, 2015, 45, 1463-1478.	3.1	355
269	In silicotools used for compound selection during target-based drug discovery and development. Expert Opinion on Drug Discovery, 2015, 10, 901-923.	2.5	16
270	How to handle an industry in disruption: Intervene or laissez-faire?. Science Translational Medicine, 2015, 7, 286ps12.	5.8	1
271	Significance and future role of microbial resource centers. Systematic and Applied Microbiology, 2015, 38, 258-265.	1.2	44
272	Syn-Ethyl 1-hydroxy-7-methoxy-2,3-dihydro-1H-pyrrolo[3,4-b]quinolone-3-carboxylate HCl Salt. MolBank, 2015, 2015, M846.	0.2	1
273	Organs-on-chips at the frontiers of drug discovery. Nature Reviews Drug Discovery, 2015, 14, 248-260.	21.5	930
274	The safety, efficacy and regulatory triangle in drug development: Impact for animal models and the use of animals. European Journal of Pharmacology, 2015, 759, 3-13.	1.7	41
275	Lead optimization attrition analysis (LOAA): a novel and general methodology for medicinal chemistry. Drug Discovery Today, 2015, 20, 978-987.	3.2	15

#	Article	IF	Citations
276	Innovative medicines: new regulatory procedures for the third millennium. Expert Opinion on Biological Therapy, 2015, 15, 5-8.	1.4	6
277	Biomarker use is associated with reduced clinical trial failure risk in metastatic melanoma. Biomarkers in Medicine, 2015, 9, 13-23.	0.6	14
278	White spots in pharmaceutical pipelinesâ€“EMA identifies potential areas of unmet medical needs. Expert Review of Clinical Pharmacology, 2015, 8, 353-360.	1.3	7
279	Sources for Leads: Natural Products and Libraries. Handbook of Experimental Pharmacology, 2015, 232, 91-123.	0.9	7
280	CETSA: a target engagement assay with potential to transform drug discovery. Future Medicinal Chemistry, 2015, 7, 975-978.	1.1	40
281	Biomarkers in Pharmaceutical Research. Clinical Chemistry, 2015, 61, 1343-1353.	1.5	48
282	Academicâ€“Pharma drug discovery alliances: seeking ways to eliminate the valley of death. Future Medicinal Chemistry, 2015, 7, 1891-1899.	1.1	10
283	Computational allosteric ligand binding site identification on Ras proteins. Acta Biochimica Et Biophysica Sinica, 2016, 48, 3-10.	0.9	24
284	Crowdsourced â€˜R&Dâ€™ and medical research: Table 1. British Medical Bulletin, 2015, 115, 67-76.	2.7	28
285	Health Security Preparedness and Industry Trends. Health Security, 2015, 13, 74-81.	0.9	1
286	Chemical genetics and regeneration. Future Medicinal Chemistry, 2015, 7, 2263-2283.	1.1	4
287	The importance of triaging in determining the quality of output from high-throughput screening. Future Medicinal Chemistry, 2015, 7, 1847-1852.	1.1	17
288	Identification of drug candidates and repurposing opportunities through compoundâ€“target interaction networks. Expert Opinion on Drug Discovery, 2015, 10, 1333-1345.	2.5	54
289	Unknown unknowns in biomedical research: does an inability to deal with ambiguity contribute to issues of irreproducibility?. Biochemical Pharmacology, 2015, 97, 133-136.	2.0	35
290	Identification of in vitro and in vivo disconnects using transcriptomic data. BMC Genomics, 2015, 16, 615.	1.2	13
291	Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnology Advances, 2015, 33, 1582-1614.	6.0	1,871
292	Increasing disparities between resource inputs and outcomes, as measured by certain health deliverables, in biomedical research. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11335-11340.	3.3	75
293	Increased complexity in carcinomas: Analyzing and modeling the interaction of human cancer cells with their microenvironment. Seminars in Cancer Biology, 2015, 35, 107-124.	4.3	60

#	Article	IF	Citations
294	Trends in Modern Drug Discovery. Handbook of Experimental Pharmacology, 2015, 232, 3-22.	0.9	38
295	Mathematical Models in Biology. , 2015, , .		3
296	Intraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats. Journal of Nuclear Medicine, 2015, 56, 1793-1799.	2.8	10
297	A decade of innovation in pharmaceutical R&D: the Chorus model. Nature Reviews Drug Discovery, 2015, 14, 17-28.	21.5	60
298	A sensitive and microscale method for drug screening combining affinity probes and single molecule fluorescence correlation spectroscopy. Analyst, The, 2015, 140, 1207-1214.	1.7	12
299	Signaling networks in MS: A systems-based approach to developing new pharmacological therapies. Multiple Sclerosis Journal, 2015, 21, 138-146.	1.4	24
300	High-growth firms in changing competitive environments: the US pharmaceutical industry (1963 to) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	4.4	59
301	Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. ALTEX: Alternatives To Animal Experimentation, 2016, 33, 272-321.	0.9	214
303	Comparative In Vitro Immune Stimulation Analysis of Primary Human B Cells and B Cell Lines. Journal of Immunology Research, 2016, 2016, 1-9.	0.9	32
304	Cells and Organs on Chipâ€"A Revolutionary Platform for Biomedicine. , 0, , .		7
305	Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics. Frontiers in Microbiology, 2016, 7, 1209.	1.5	135
306	Utility of Induced Pluripotent Stem Cells for the Study and Treatment of Genetic Diseases: Focus on Childhood Neurological Disorders. Frontiers in Molecular Neuroscience, 2016, 9, 78.	1.4	29
307	Can you teach old drugs new tricks?. Nature, 2016, 534, 314-316.	13.7	484
308	Complementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets. Biomedicines, 2016, 4, 27.	1.4	23
309	Mimicking the Kidney: A Key Role in Organ-on-Chip Development. Micromachines, 2016, 7, 126.	1.4	32
310	Using Clinical Trial Simulators to Analyse the Sources of Variance in Clinical Trials of Novel Therapies for Acute Viral Infections. PLoS ONE, 2016, 11, e0156622.	1.1	10
311	Preclinical Cancer Models with the Potential to Predict Clinical Response. , 2016, , 97-122.		0
312	Opportunities and Challenges for Drug Development: Publicâ€"Private Partnerships, Adaptive Designs and Big Data. Frontiers in Pharmacology, 2016, 7, 461.	1.6	60

#	Article	IF	Citations
313	Overview of DNA repair pathways, current targets, and clinical trials bench to clinic. , 2016, , 1-54.		6
314	Establishment of a Tumourâ€“Stroma Airway Model (OncoCilAir) to Accelerate the Development of Human Therapies against Lung Cancer. ATLA Alternatives To Laboratory Animals, 2016, 44, 479-485.	0.7	12
316	Reformulating the entropic contribution in molecular docking scoring functions. Journal of Computational Chemistry, 2016, 37, 1819-1827.	1.5	10
317	Chemical philanthropy: a path forward for antibiotic discovery?. Future Medicinal Chemistry, 2016, 8, 925-929.	1.1	23
318	Precision medicine in the age of big data: The present and future role of largeâ€scale unbiased sequencing in drug discovery and development. Clinical Pharmacology and Therapeutics, 2016, 99, 198-207.	2.3	42
319	Developing New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward. American Journal of Transplantation, 2016, 16, 1094-1101.	2.6	59
320	Scaffold Diversity Synthesis and Its Application in Probe and Drug Discovery. Angewandte Chemie - International Edition, 2016, 55, 7586-7605.	7.2	150
321	Research Funding: the Case for a Modified Lottery. MBio, 2016, 7, e00422-16.	1.8	75
322	A Distributed Network for Intensive Longitudinal Monitoring in Metastatic Triple-Negative Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 8-17.	2.3	21
323	Leveraging Industryâ€Academia Collaborations in Adaptive Biomedical Innovation. Clinical Pharmacology and Therapeutics, 2016, 100, 647-653.	2.3	5
324	Healthcare Commercialization Programs: Improving the Efficiency of Translating Healthcare Innovations From Academia Into Practice. IEEE Journal of Translational Engineering in Health and Medicine, 2016, 4, 1-7.	2.2	13
325	Using Systems Pharmacology to Advance Oncology Drug Development. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 421-463.	0.2	1
326	Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery. Scientific Reports, 2016, 6, 28951.	1.6	192
327	A network-based drug repositioning infrastructure for precision cancer medicine through targeting significantly mutated genes in the human cancer genomes. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 681-691.	2.2	46
328	Facilitating the commercialization and use of organ platforms generated by the microphysiological systems (Tissue Chip) program through publicâ€“private partnerships. Computational and Structural Biotechnology Journal, 2016, 14, 207-210.	1.9	34
329	The evolution of drug discovery: from phenotypes to targets, and back. MedChemComm, 2016, 7, 788-798.	3.5	31
330	Cell permeability beyond the rule of 5. Advanced Drug Delivery Reviews, 2016, 101, 42-61.	6.6	196
331	Repurposing Vitamin D as an Anticancer Drug. Clinical Oncology, 2016, 28, 36-41.	0.6	14

#	Article	IF	Citations
332	Drugging the undruggable: gabapentin, pregabalin and the calcium channel Î±₂Î´ subunit. Critical Reviews in Biochemistry and Molecular Biology, 2016, 51, 246-256.	2.3	21
333	I. Dissociation free energies of drugâ€“receptor systems via non-equilibrium alchemical simulations: a theoretical framework. Physical Chemistry Chemical Physics, 2016, 18, 14991-15004.	1.3	28
334	Phenome-Wide Association Studies as a Tool to Advance Precision Medicine. Annual Review of Genomics and Human Genetics, 2016, 17, 353-373.	2.5	193
335	The analysis of the market success of FDA approvals by probing top 100 bestselling drugs. Journal of Computer-Aided Molecular Design, 2016, 30, 381-389.	1.3	10
336	Research paradigms and useful inventions in medicine: Patents and licensing by teams of clinical and basic scientists in Academic Medical Centers. Research Policy, 2016, 45, 1499-1511.	3.3	32
337	II. Dissociation free energies in drugâ€“receptor systems via nonequilibrium alchemical simulations: application to the FK506-related immunophilin ligands. Physical Chemistry Chemical Physics, 2016, 18, 15005-15018.	1.3	34
338	A new chapter in innovation. Nature, 2016, 533, S54-S55.	13.7	9
339	Combination therapeutics in complex diseases. Journal of Cellular and Molecular Medicine, 2016, 20, 2231-2240.	1.6	76
340	Zebrafish small molecule screens: Taking the phenotypic plunge. Computational and Structural Biotechnology Journal, 2016, 14, 350-356.	1.9	24
341	Comparison of cancer cells cultured in 2D vs 3D reveals differences in AKT/mTOR/S6-kinase signaling and drug response. Journal of Cell Science, 2017, 130, 203-218.	1.2	308
342	The promises of quantitative systems pharmacology modelling for drugÂdevelopment. Computational and Structural Biotechnology Journal, 2016, 14, 363-370.	1.9	77
343	Patents as a Spur to Subsequent Innovation? Evidence from Pharmaceuticals. American Economic Journal: Applied Economics, 2016, 8, 189-221.	1.5	10
344	A Pressing Need for Pharmacotherapy Development to Treat Drug Addiction. International Review of Neurobiology, 2016, 126, 15-38.	0.9	1
345	Late-stage pharmaceutical R&D and pricing policies under two-stage regulation. Journal of Health Economics, 2016, 50, 298-311.	1.3	15
346	Understanding Cryptic Pocket Formation in Protein Targets by Enhanced Sampling Simulations. Journal of the American Chemical Society, 2016, 138, 14257-14263.	6.6	151
347	Increasing experimental reproducibility, from antibodies to protein arrays. Drug Discovery Today, 2016, 21, 1197-1199.	3.2	0
348	The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system. Expert Opinion on Drug Discovery, 2016, 11, 939-956.	2.5	10
349	Reflection of successful anticancer drug development processes in the literature. Drug Discovery Today, 2016, 21, 1740-1744.	3.2	11

#	Article	IF	Citations
350	The High Cost of Prescription Drugs in the United States. JAMA - Journal of the American Medical Association, 2016, 316, 858.	3.8	445
351	Microengineered cancer-on-a-chip platforms to study the metastatic microenvironment. Lab on A Chip, 2016, 16, 4063-4081.	3.1	100
352	Connection Map for Compounds (CMC): A Server for Combinatorial Drug Toxicity and Efficacy Analysis. Journal of Chemical Information and Modeling, 2016, 56, 1615-1621.	2.5	10
353	Industryâ€"Academic Relationship in a New Era of Drug Discovery. Journal of Clinical Oncology, 2016, 34, 3570-3575.	0.8	10
355	Graduate Education in Pharmacology: Addressing the need for specialized training for pharmaceutical and biotechnology careers. Pharmacological Research, 2016, 113, 327-331.	3.1	1
356	Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles. ACS Central Science, 2016, 2, 687-701.	5.3	68
357	A Data-Driven Approach to Predicting Successes and Failures of Clinical Trials. Cell Chemical Biology, 2016, 23, 1294-1301.	2.5	154
358	Should network biology be used for drug discovery?. Expert Opinion on Drug Discovery, 2016, 11, 1135-1137.	2.5	4
359	Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare Diseases. Clinical Pharmacology and Therapeutics, 2016, 100, 339-341.	2.3	5
360	Next-generation phenotypic screening. Future Medicinal Chemistry, 2016, 8, 1331-1347.	1.1	39
361	Anaerobes as Sources of Bioactive Compounds and Health Promoting Tools. Advances in Biochemical Engineering/Biotechnology, 2016, 156, 433-464.	0.6	12
362	Ionic liquids as a potential tool for drug delivery systems. MedChemComm, 2016, 7, 1881-1897.	3.5	216
367	Quality guidelines for oral drug candidates: dose, solubility and lipophilicity. Drug Discovery Today, 2016, 21, 1719-1727.	3.2	83
368	ARQiv-HTS, a versatile whole-organism screening platform enabling in vivo drug discovery at high-throughput rates. Nature Protocols, 2016, 11, 2432-2453.	5.5	50
369	Training the Next Generation of InnovatorsÂinÂDermatology. Journal of Investigative Dermatology, 2016, 136, 2113-2115.	0.3	8
370	Disciplined approach to drug discovery and early development. Science Translational Medicine, 2016, 8, 349ps15.	5.8	79
371	Principles of dynamical modularity in biological regulatory networks. Scientific Reports, 2016, 6, 21957.	1.6	33
372	Non-Specificity of Drug-Target Interactions â€" Consequences for Drug Discovery. ACS Symposium Series, 2016, , 91-142.	0.5	2

#	Article	IF	Citations
373	Re-energizing the Development of Pain Therapeutics in Light of the Opioid Epidemic. Neuron, 2016, 92, 294-297.	3.8	56
374	Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files. Molecular Diversity, 2016, 20, 789-803.	2.1	6
375	Evolutionary prediction of medicinal properties in the genus Euphorbia L.. Scientific Reports, 2016, 6, 30531.	1.6	45
376	Immuno-psychiatry: an agenda for clinical practice and innovative research. BMC Medicine, 2016, 14, 173.	2.3	51
377	Biomarkers for Drug Discovery and Development. Journal of the Mass Spectrometry Society of Japan, 2016, 64, 55-59.	0.0	0
378	GerÃ¼stdiversitÃ¤tsbasierte Synthese und ihre Anwendung bei der Sondenâ€•und Wirkstoffsuche. Angewandte Chemie, 2016, 128, 7712-7732.	1.6	33
380	Changing R&D models in research-based pharmaceutical companies. Journal of Translational Medicine, 2016, 14, 105.	1.8	231
381	Current Issues in Drug Development. , 2016, , 7-18.		0
382	Data Mining in Drug Discovery and Design. , 2016, , 181-193.		2
383	Towards cheminformatics-based estimation of drug therapeutic index: Predicting the protective index of anticonvulsants using a new quantitative structure-index relationship approach. Journal of Molecular Graphics and Modelling, 2016, 67, 102-110.	1.3	3
384	DrugE-Rank: improving drugâ€“target interaction prediction of new candidate drugs or targets by ensemble learning to rank. Bioinformatics, 2016, 32, i18-i27.	1.8	115
385	Human ex-vivo action potential model for pro-arrhythmia risk assessment. Journal of Pharmacological and Toxicological Methods, 2016, 81, 183-195.	0.3	33
386	Network pharmacology of cancer: From understanding of complex interactomes to the design of multi-target specific therapeutics from nature. Pharmacological Research, 2016, 111, 290-302.	3.1	156
387	Innovator Organizations in New Drug Development: Assessing the Sustainability of the Biopharmaceutical Industry. Cell Chemical Biology, 2016, 23, 644-653.	2.5	12
388	Modeling ADMET. Methods in Molecular Biology, 2016, 1425, 63-83.	0.4	36
389	Managing risks in drug discovery: reproducibility of published findings. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 353-360.	1.4	37
390	Cardiovascular Organ-on-a-Chip Platforms for Drug Discovery and Development. Applied in Vitro Toxicology, 2016, 2, 82-96.	0.6	124
391	Learning to shield â€“ Policy learning in socio-technical transitions. Environmental Innovation and Societal Transitions, 2016, 18, 181-200.	2.5	19

#	Article	IF	Citations
392	Organizational effectiveness: a key to R&D productivity. Nature Reviews Drug Discovery, 2016, 15, 441-442.	21.5	10
393	Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era. Briefings in Bioinformatics, 2016, 18, bbw051.	3.2	57
395	Success rates for product development strategies in new drug development. Journal of Clinical Pharmacy and Therapeutics, 2016, 41, 198-202.	0.7	6
396	Trends in Innovation and the Business of Drug Discovery. , 2016, , 29-55.		2
397	The New Health Bioeconomy. , 2016, , .		17
398	The impact of clinical trial monitoring approaches on data integrity and costâ€"a review of current literature. European Journal of Clinical Pharmacology, 2016, 72, 399-412.	0.8	38
399	Prediction of diseaseâ€"geneâ€"drug relationships following a differential network analysis. Cell Death and Disease, 2016, 7, e2040-e2040.	2.7	63
400	Advances and Challenges in Recapitulating Human Pulmonary Systems: At the Cusp of Biology and Materials. ACS Biomaterials Science and Engineering, 2016, 2, 473-488.	2.6	25
401	Ten Years of Medicinal Chemistry (2005â€"2014) in the Journal of Medicinal Chemistry: Country of Contributors, Topics, and Publicâ€"Private Partnerships. Journal of Medicinal Chemistry, 2016, 59, 7352-7359.	2.9	5
402	Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new targets. Drug Resistance Updates, 2016, 26, 10-27.	6.5	30
403	Engineering large animal models of human disease. Journal of Pathology, 2016, 238, 247-256.	2.1	119
404	Biomarkers and personalized medicine: current status and further perspectives with special focus on dermatology. Experimental Dermatology, 2016, 25, 333-339.	1.4	31
405	Compound annotation with real time cellular activity profiles to improve drug discovery. Expert Opinion on Drug Discovery, 2016, 11, 269-280.	2.5	3
406	Evolution of strategies to improve preclinical cardiac safety testing. Nature Reviews Drug Discovery, 2016, 15, 457-471.	21.5	323
407	Molecular inflation, attrition and the rule of five. Advanced Drug Delivery Reviews, 2016, 101, 22-33.	6.6	144
408	Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. Chemical Research in Toxicology, 2016, 29, 564-616.	1.7	148
409	Rational design of liposomal drug delivery systems, a review: Combined experimental and computational studies of lipid membranes, liposomes and their PEGylation. Biochimica Et Biophysica Acta - Biomembranes, 2016, 1858, 2334-2352.	1.4	146
410	Precision Medicine, Cardiovascular Disease and Hunting Elephants. Progress in Cardiovascular Diseases, 2016, 58, 651-660.	1.6	34

#	Article	IF	Citations
411	Efficiencies of platform clinical trials: A vision of the future. Clinical Trials, 2016, 13, 358-366.	0.7	209
412	Open Access Could Transform Drug Discovery: A Case Study of JQ1. Expert Opinion on Drug Discovery, 2016, 11, 321-332.	2.5	28
413	Developments of mass spectrometry-based technologies for effective drug development linked with clinical proteomes. Drug Metabolism and Pharmacokinetics, 2016, 31, 3-11.	1.1	9
414	Open innovation in early drug discovery: roadmaps and roadblocks. Drug Discovery Today, 2016, 21, 779-788.	3.2	23
415	Harnessing QbD, Programming Languages, and Automation for Reproducible Biology. Trends in Biotechnology, 2016, 34, 214-227.	4.9	44
416	Target Identification of Compounds from a Cell Viability Phenotypic Screen Using a Bead/Lysate-Based Affinity Capture Platform. Journal of Biomolecular Screening, 2016, 21, 201-211.	2.6	16
417	Innovative New Drugs for Serious Nonlethal Diseases. JAMA Dermatology, 2016, 152, 139.	2.0	2
418	Why and how have drug discovery strategies in pharma changed? What are the new mindsets?. Drug Discovery Today, 2016, 21, 239-249.	3.2	62
419	How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets. Journal of Medicinal Chemistry, 2016, 59, 2312-2327.	2.9	248
420	Abductive Reasoning: How Innovators Navigate in the Labyrinth of Complex Product Innovation. Organization Studies, 2016, 37, 131-159.	3.8	68
421	Translating Neurogenomics Into New Medicines. Biological Psychiatry, 2016, 79, 650-656.	0.7	12
422	Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. European Heart Journal, 2016, 37, 747-754.	1.0	62
423	The Dynamics of Pharmaceutical Regulation and R&D Investments. Journal of Public Economic Theory, 2017, 19, 121-141.	0.6	11
424	Biosynthesis of the microtubule-destabilizing diterpene pseudolaric acid B from golden larch involves an unusual diterpene synthase. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 974-979.	3.3	21
425	Antibiotic discovery throughout the Small World Initiative: A molecular strategy to identify biosynthetic gene clusters involved in antagonistic activity. MicrobiologyOpen, 2017, 6, e00435.	1.2	52
426	Progress does not just come in giant leaps: adapting techniques for the study of inflammation to novel applications. Inflammation Research, 2017, 66, 1-12.	1.6	1
427	Integrated, High-Throughput, Multiomics Platform Enables Data-Driven Construction of Cellular Responses and Reveals Global Drug Mechanisms of Action. Journal of Proteome Research, 2017, 16, 1364-1375.	1.8	34
428	Exaptation, serendipity and aging. Mechanisms of Ageing and Development, 2017, 163, 30-35.	2.2	6

#	Article	IF	Citations
429	Measuring the effectiveness and impact of an open innovation platform. Drug Discovery Today, 2017, 22, 776-785.	3.2	33
430	Tiered analytics for purity assessment of macrocyclic peptides in drug discovery: Analytical consideration and method development. Journal of Pharmaceutical and Biomedical Analysis, 2017, 138, 166-174.	1.4	4
431	Computational protein design: a review. Journal of Physics Condensed Matter, 2017, 29, 143001.	0.7	45
432	New Modalities for Challenging Targets in Drug Discovery. Angewandte Chemie - International Edition, 2017, 56, 10294-10323.	7.2	275
433	Application of Pharmacokinetics and Pharmacodynamics in Product Life Cycle Management. A Case Study with a Carbidopa-Levodopa Extended-Release Formulation. AAPS Journal, 2017, 19, 607-618.	2.2	6
434	Neue ModalitÃten fÃ¼r schwierige Zielstrukturen in der Wirkstoffentwicklung. Angewandte Chemie, 2017, 129, 10428-10459.	1.6	39
435	Role of Academic Drug Discovery in the Quest for New CNS Therapeutics. ACS Chemical Neuroscience, 2017, 8, 429-431.	1.7	19
436	Occlusion in the Flow of New Drugs for Cardiovascular Disease. Clinical Pharmacology and Therapeutics, 2017, 102, 246-253.	2.3	7
437	Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. Assay and Drug Development Technologies, 2017, 15, 113-119.	0.6	30
438	Introducing Therioepistemology: the study of how knowledge is gained from animal research. Lab Animal, 2017, 46, 103-113.	0.2	84
439	Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use. MAbs, 2017, 9, 742-755.	2.6	24
440	A Blind Test of Computational Technique for Predicting the Likelihood of Peptide Sequences to Cyclize. Journal of Physical Chemistry Letters, 2017, 8, 2310-2315.	2.1	7
441	On the role of forces governing particulate interactions in pharmaceutical systems: A review. International Journal of Pharmaceutics, 2017, 526, 516-537.	2.6	20
443	Outlook for the Future. AAPS Advances in the Pharmaceutical Sciences Series, 2017, , 421-447.	0.2	0
444	Pharmaceutical Industry Performance. AAPS Advances in the Pharmaceutical Sciences Series, 2017, , 3-25.	0.2	0
445	Efficient design of clinical trials and epidemiological research: is it possible?. Nature Reviews Cardiology, 2017, 14, 493-501.	6.1	34
446	Evaluating Philosophy as Exploratory Research. Metaphilosophy, 2017, 48, 227-244.	0.2	3
447	Drotaverine â€“ a Concealed Cytostatic!. Archiv Der Pharmazie, 2017, 350, e1600289.	2.1	4

#	Article	IF	Citations
448	The translational potential of humanÂinduced pluripotent stem cells for clinical neurology. Cell Biology and Toxicology, 2017, 33, 129-144.	2.4	18
449	Do large mergers increase or decrease the productivity of pharmaceutical R&D?. Drug Discovery Today, 2017, 22, 1749-1753.	3.2	12
451	Network mirroring for drug repositioning. BMC Medical Informatics and Decision Making, 2017, 17, 55.	1.5	18
452	A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor. Nature Chemical Biology, 2017, 13, 771-778.	3.9	39
453	Engineering in vitro models of hepatofibrogenesis. Advanced Drug Delivery Reviews, 2017, 121, 147-157.	6.6	45
454	Mining the Genome for Therapeutic Targets. Diabetes, 2017, 66, 1770-1778.	0.3	14
455	Applications of CRISPR genome editing technology in drug target identification and validation. Expert Opinion on Drug Discovery, 2017, 12, 541-552.	2.5	15
456	Obstacles and opportunities in Chinese pharmaceutical innovation. Globalization and Health, 2017, 13, 21.	2.4	24
457	WAT-on-a-chip: a physiologically relevant microfluidic system incorporating white adipose tissue. Lab on A Chip, 2017, 17, 1645-1654.	3.1	93
458	The academicâ€“industrial complex: navigating the translational and cultural divide. Drug Discovery Today, 2017, 22, 976-993.	3.2	13
459	Analysis of FDA-approved imaging agents. Drug Discovery Today, 2017, 22, 1077-1083.	3.2	12
460	Testing regimes in clinical trials: Evidence from four polio vaccine trajectories. Research Policy, 2017, 46, 475-484.	3.3	11
461	Microbial Resource Centers Contribute to Bioprospecting of Bacteria and Filamentous Microfungi. Topics in Biodiversity and Conservation, 2017, , 51-79.	0.3	10
462	Requirements for Using iPSC-Based Cell Models for Assay Development in Drug Discovery. Advances in Biochemical Engineering/Biotechnology, 2017, 163, 207-220.	0.6	7
463	Inventive processes in nature: from information origin in chemical evolution to technological exhaustion. Earth Perspectives -- Transdisciplinarity Enabled, 2017, 4, .	1.4	1
464	Human induced pluripotent stem cell-derived vascular smooth muscle cells: differentiation and therapeutic potential. Cardiovascular Research, 2017, 113, 1282-1293.	1.8	31
465	A multiscale study of the role of dynamin in the regulation of glucose uptake. Integrative Biology (United Kingdom), 2017, 9, 810-819.	0.6	7
466	Designer bacteria as intratumoural enzyme biofactories. Advanced Drug Delivery Reviews, 2017, 118, 8-23.	6.6	18

#	Article	IF	Citations
467	PhID: An Open-Access Integrated Pharmacology Interactions Database for Drugs, Targets, Diseases, Genes, Side-Effects, and Pathways. Journal of Chemical Information and Modeling, 2017, 57, 2395-2400.	2.5	9
468	An overview of FDA-approved vaccines & their innovators. Expert Review of Vaccines, 2017, 16, 1253-1266.	2.0	19
469	Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening. Nature Communications, 2017, 8, 16081.	5.8	57
470	A comparative effectiveness study of eSource used for data capture for a clinical research registry. International Journal of Medical Informatics, 2017, 103, 89-94.	1.6	29
471	The Business of Anti-Aging Science. Trends in Biotechnology, 2017, 35, 1062-1073.	4.9	127
472	Intraâ€Target Microdosing â€“ A Novel Drug Development Approach: Proof of Concept, Safety, and Feasibility Study in Humans. Clinical and Translational Science, 2017, 10, 351-359.	1.5	6
473	The Burden of the â€œFalseâ€Negativesâ€•in Clinical Development: Analyses of Current and Alternative Scenarios and Corrective Measures. Clinical and Translational Science, 2017, 10, 470-479.	1.5	19
474	The octet rule in chemical space: generating virtual molecules. Molecular Diversity, 2017, 21, 769-778.	2.1	0
475	Rising to the challenge: applying biofabrication approaches for better drug and chemical product development. Biofabrication, 2017, 9, 033001.	3.7	22
476	In silico structure-based approaches to discover protein-protein interaction-targeting drugs. Methods, 2017, 131, 22-32.	1.9	69
477	Scientific real-time research problem-solving and pharmaceutical innovation. African Journal of Science, Technology, Innovation and Development, 2017, 9, 425-435.	0.8	7
478	An Escalation for Bivariate Binary Endpoints Controlling the Risk of Overtoxicity (EBE-CRO): Managing Efficacy and Toxicity in Early Oncology Clinical Trials. Journal of Biopharmaceutical Statistics, 2017, 27, 1054-1072.	0.4	4
479	Health state dependent multiphoton induced autofluorescence in human 3D in vitro lung cancer model. Scientific Reports, 2017, 7, 16233.	1.6	10
480	The 3D OrbiSIMSâ€”label-free metabolic imaging with subcellular lateral resolution and high mass-resolving power. Nature Methods, 2017, 14, 1175-1183.	9.0	327
483	Crisis in Infectious Diseases: 2 Decades Later. Clinical Infectious Diseases, 2017, 64, 823-828.	2.9	20
484	Labelâ€Free Dynamic Mass Redistribution and Bioâ€Impedance Methods for Drug Discovery. Current Protocols in Pharmacology, 2017, 77, 9.24.1-9.24.21.	4.0	8
485	Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact. Pharmaceutical Research, 2017, 34, 1985-1999.	1.7	31
486	Unlocking the potential of established products: toward new incentives rewarding innovation in Europe. Journal of Market Access & Health Policy, 2017, 5, 1298190.	0.8	13

#	Article	IF	Citations
487	Investigating the effects of Orexin-A on thermogenesis in human deep neck brown adipose tissue. International Journal of Obesity, 2017, 41, 1646-1653.	1.6	17
488	Process Model for Enhancing Yield in Sterile Drug Product Manufacturing. Journal of Pharmaceutical Innovation, 2017, 12, 194-205.	1.1	3
489	Value-Based Pharmaceutical Pricing From the Patient Perspective Could Incentivize Innovation. Pharmaceutical Medicine, 2017, 31, 149-153.	1.0	5
490	Industrial medicinal chemistry insights: neuroscience hit generation at Janssen. Drug Discovery Today, 2017, 22, 1478-1488.	3.2	5
491	Accelerating glioblastoma drug discovery: Convergence of patient-derived models, genome editing and phenotypic screening. Molecular and Cellular Neurosciences, 2017, 80, 198-207.	1.0	20
492	Old drugs with new skills: fenoprofen as an allosteric enhancer at melanocortin receptor 3. Cellular and Molecular Life Sciences, 2017, 74, 1335-1345.	2.4	24
493	Challenging the dominant logic in the healthcare industry: the case of precision medicine. Technology Analysis and Strategic Management, 2017, 29, 843-856.	2.0	2
494	Using Big Data to Discover Diagnostics and Therapeutics forÂGastrointestinal and Liver Diseases. Gastroenterology, 2017, 152, 53-67.e3.	0.6	61
495	Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations. Drug Discovery Today, 2017, 22, 327-339.	3.2	64
497	Building a drug development database: challenges in reliable data availability. Drug Development and Industrial Pharmacy, 2017, 43, 74-78.	0.9	6
498	Repurposing N,N'-bis-(arylamidino)-1,4-piperazinedicarboxamidines: An unexpected class of potent inhibitors of cholinesterases. European Journal of Medicinal Chemistry, 2017, 125, 430-434.	2.6	11
499	Design of efficient computational workflows for in silico drug repurposing. Drug Discovery Today, 2017, 22, 210-222.	3.2	139
500	Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer. Cancer Research, 2017, 77, 566-578.	0.4	38
501	Integrating Bio-ontologies and Controlled Clinical Terminologies: From Base Pairs to Bedside Phenotypes. Methods in Molecular Biology, 2017, 1446, 275-287.	0.4	1
502	Concise Review: Organ Engineering: Design, Technology, and Integration. Stem Cells, 2017, 35, 51-60.	1.4	48
503	Overcoming the Declining Trends inÂInnovation and Investment in Cardiovascular Therapeutics. JACC Basic To Translational Science, 2017, 2, 613-625.	1.9	20
504	The Rising Cost of Developing Cardiovascular Therapies and Reproducibility in Translational Research. JACC Basic To Translational Science, 2017, 2, 627-629.	1.9	5
506	Towards More Inclusive IP Analysis by Frontier Tools. , 2017, , .		1

#	Article	IF	Citations
508	Label-Free Screening Technologies. , 2017, , 416-433.		1
509	Enhancing the Promise of Drug Repositioning through Genetics. Frontiers in Pharmacology, 2017, 8, 896.	1.6	59
510	Why Pharma Should Care About the Valley of Death. , 2017, , 41-48.		0
511	A Systematic Review of Computational Drug Discovery, Development, and Repurposing for Ebola Virus Disease Treatment. Molecules, 2017, 22, 1777.	1.7	28
512	Drug discovery. , 2017, , 281-420.		1
513	Future of Medicinal Chemistry: Next-Generation Therapeutics. , 2017, , 326-348.		0
514	Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations. International Journal of Molecular Sciences, 2017, 18, 448.	1.8	15
515	Systematic integration of biomedical knowledge prioritizes drugs for repurposing. ELife, 2017, 6, .	2.8	333
516	Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics. Frontiers in Oncology, 2017, 7, 273.	1.3	189
517	High-Content Monitoring of Drug Effects in a 3D Spheroid Model. Frontiers in Oncology, 2017, 7, 293.	1.3	117
518	Bioprospecting saline gradient of a Wildlife Sanctuary for bacterial diversity and antimicrobial activities. BMC Research Notes, 2017, 10, 397.	0.6	3
519	Morphological Freedom as a Basic Human Right: Three Arguments. SSRN Electronic Journal, 2017, , .	0.4	0
520	Drug discovery. , 2017, , 183-279.		1
521	Research and discovery. , 2017, , 421-436.		0
522	Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker Based Approaches. Journal of Molecular Biomarkers & Diagnosis, 2017, 08, .	0.4	25
523	Machine-Learning Models for Predicting Drug Approvals and Clinical-Phase Transitions. SSRN Electronic Journal, 2017, , .	0.4	1
524	Structural Chemogenomics Databases to Navigate Proteinâ€“Ligand Interaction Space. , 2017, , 444-471.		1
525	Backgrounder. , 2017, , 3-29.		0

#	Article	IF	Citations
526	Bioactive Natural Product and Superacid Chemistry for Lead Compound Identification: A Case Study of Selective hCA III and L-Type Ca2+ Current Inhibitors for Hypotensive Agent Discovery. Molecules, 2017, 22, 915.	1.7	4
527	The probabilistic innovation theoretical framework. South African Journal of Economic and Management Sciences, 2017, 20, .	0.4	0
528	Preclinical Pharmacology and Toxicology - Contributions to the Translational Interface â˜†. , 2017, , .		4
529	Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays. Oncotarget, 2017, 8, 8854-8866.	0.8	78
531	Sharing R&D Risk in Healthcare via FDA Hedges. SSRN Electronic Journal, 2017, , .	0.4	1
532	Endogenous Productivity of Demand-Induced R&D: Evidence from Pharmaceuticals. SSRN Electronic Journal, 2017, , .	0.4	0
533	US Pharma's Financialized Business Model. SSRN Electronic Journal, 0, , .	0.4	44
534	Do Statins Improve Survival in Small-Cell Lung Cancer?. Journal of Clinical Oncology, 2017, 35, 1497-1498.	0.8	4
535	Multiobjective Optimization of Biological and Physical Properties in Drug Discovery. , 2017, , 64-93.		0
536	One Lab, Two Firms, Many Possibilities: On R&D Outsourcing in the Biopharmaceutical Industry. SSRN Electronic Journal, 0, , .	0.4	3
537	Application of Metabolomics to Quality Control of Natural Product Derived Medicines. Biomolecules and Therapeutics, 2017, 25, 559-568.	1.1	41
538	Prediction of Chemical Multi-target Profiles and Adverse Outcomes with Systems Toxicology. Current Medicinal Chemistry, 2017, 24, 1705-1720.	1.2	3
539	Predicting Target and Chemical Druggability. , 2017, , 429-439.		2
540	Funding Long Shots. SSRN Electronic Journal, 2017, , .	0.4	6
541	Attack or Defend? The Role of Institutional Context on Patent Litigation Strategies. Journal of Management, 2018, 44, 1226-1249.	6.3	12
542	High-throughput organ-on-a-chip systems: Current status and remaining challenges. Current Opinion in Biomedical Engineering, 2018, 6, 33-41.	1.8	113
543	Prediction of protein-ligand interactions from paired protein sequence motifs and ligand substructures. , 2018, , .		6
545	Translating translation. Nature Reviews Drug Discovery, 2018, 17, 455-456.	21.5	67

#	Article	IF	Citations
547	The End of Medicine as We Know It: Introduction to the New Journal, Systems Medicine. Systems Medicine (New Rochelle, N Y), 2018, 1, 1-2.	1.4	8
548	Challenges and needs in experimental therapies for multiple sclerosis. Current Opinion in Neurology, 2018, 31, 263-267.	1.8	9
549	Transforming nanomedicine manufacturing toward Quality by Design and microfluidics. Advanced Drug Delivery Reviews, 2018, 128, 115-131.	6.6	75
550	Organs-on-a-chip: Current applications and consideration points for inÂvitro ADME-Tox studies. Drug Metabolism and Pharmacokinetics, 2018, 33, 49-54.	1.1	80
551	Professional medical associations and the opportunity to promote breakthrough biomedical innovation. Drug Discovery Today, 2018, 23, 1453-1456.	3.2	1
552	Contribution of NIH funding to new drug approvals 2010â€“2016. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2329-2334.	3.3	150
553	Multistage inhibitors of the malaria parasite: Emerging hope for chemoprotection and malaria eradication. Medicinal Research Reviews, 2018, 38, 1511-1535.	5.0	26
554	Inventing new therapies without reinventing the wheel: the power of drug repurposing. British Journal of Pharmacology, 2018, 175, 165-167.	2.7	55
555	Active Search for Computerâ€aided Drug Design. Molecular Informatics, 2018, 37, 1700130.	1.4	17
556	Evolutionary and genetic features of drug targets. Medicinal Research Reviews, 2018, 38, 1536-1549.	5.0	15
557	Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature Reviews Drug Discovery, 2018, 17, 167-181.	21.5	294
558	The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery?. Advanced Healthcare Materials, 2018, 7, 1701174.	3.9	66
559	A new approach to assess drug sensitivity in cells for novel drug discovery. Expert Opinion on Drug Discovery, 2018, 13, 339-346.	2.5	6
560	Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 135-146.	1.3	56
561	Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene, 2018, 37, 403-414.	2.6	74
562	Chemogenomic Active Learning's Domain of Applicability on Small, Sparse qHTS Matrices: A Study Using Cytochrome P450 and Nuclear Hormone Receptor Families. ChemMedChem, 2018, 13, 511-521.	1.6	11
563	The Digital and In Silico Therapeutics Revolution. Computers in Health Care, 2018, , 197-214.	0.2	0
564	An on-chip intestine-liver model for multiple drugs absorption and metabolism behavior simulation. Science China Chemistry, 2018, 61, 236-242.	4.2	22

#	Article	IF	Citations
565	In silico drug combination discovery for personalized cancer therapy. BMC Systems Biology, 2018, 12, 16.	3.0	47
566	Superelectrophilic activation in superacid HF/SbF5: Expanding molecular diversity in nitrogen-containing compounds series by fluorination. Journal of Fluorine Chemistry, 2018, 214, 68-79.	0.9	6
567	Old wines in new bottles: Repurposing opportunities for Parkinson's disease. European Journal of Pharmacology, 2018, 830, 115-127.	1.7	15
568	Ensemble Docking in Drug Discovery. Biophysical Journal, 2018, 114, 2271-2278.	0.2	318
569	Strategic R&D transactions in personalized drug development. Drug Discovery Today, 2018, 23, 1334-1339.	3.2	10
570	Can we accelerate medicinal chemistry by augmenting the chemist with Big Data and artificial intelligence?. Drug Discovery Today, 2018, 23, 1373-1384.	3.2	32
571	Application of Combination Highâ€Throughput Phenotypic Screening and Target Identification Methods for the Discovery of Natural Productâ€Based Combination Drugs. Medicinal Research Reviews, 2018, 38, 504-524.	5.0	55
572	Theoretical and Biological Evaluation of the Link between Low Exercise Capacity and Disease Risk. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a029868.	2.9	44
573	Advances in alternative non-animal testing methods represent a way to find new treatments for patients. European Journal of Internal Medicine, 2018, 48, e31-e32.	1.0	2
574	Natural products for human health: an historical overview of the drug discovery approaches. Natural Product Research, 2018, 32, 1926-1950.	1.0	212
575	The paradox of sustainable innovation: The â€˜Eroomâ€™ effect (Mooreâ€™s law backwards). Journal of Cleaner Production, 2018, 172, 3487-3497.	4.6	36
576	The Current State of Peptide Drug Discovery: Back to the Future?. Journal of Medicinal Chemistry, 2018, 61, 1382-1414.	2.9	767
577	Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications. Nature Reviews Drug Discovery, 2018, 17, 19-33.	21.5	106
578	Microfluidic Cell Culture Systems for Drug Research. Integrated Analytical Systems, 2018, , 339-370.	0.4	1
579	The Opioid Epidemic: Crisis and Solutions. Annual Review of Pharmacology and Toxicology, 2018, 58, 143-159.	4.2	225
580	Mathematical modeling of efficacy and safety for anticancer drugs clinical development. Expert Opinion on Drug Discovery, 2018, 13, 5-21.	2.5	7
581	Guiding principles of value creation through collaborative innovation in pharmaceutical research. Drug Discovery Today, 2018, 23, 213-218.	3.2	5
582	3D Miniaturization of Human Organs for Drug Discovery. Advanced Healthcare Materials, 2018, 7, 1700551.	3.9	33

#	Article	IF	Citations
583	Genomeâ€wide and Phenomeâ€wide Approaches to Understand Variable Drug Actions in Electronic Health Records. Clinical and Translational Science, 2018, 11, 112-122.	1.5	36
584	Teaching Targeted Drug Discovery and Development to Healthcare Professionals. Clinical and Translational Science, 2018, 11, 277-282.	1.5	3
585	Institutionalisation of markets: The case of personalised cancer medicine in the Netherlands. Technological Forecasting and Social Change, 2018, 128, 133-143.	6.2	23
586	Development and Validation of 2D Difference Intensity Analysis for Chemical Library Screening by Proteinâ€Detected NMR Spectroscopy. ChemBioChem, 2018, 19, 448-458.	1.3	13
587	Automating drug discovery. Nature Reviews Drug Discovery, 2018, 17, 97-113.	21.5	456
588	Using Human â€˜Experiments of Natureâ€™ to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors. Drug Safety, 2018, 41, 303-311.	1.4	22
589	Dendrimers in combination with natural products and analogues as anti-cancer agents. Chemical Society Reviews, 2018, 47, 514-532.	18.7	156
590	A multi-throughput multi-organ-on-a-chip system on a plate formatted pneumatic pressure-driven medium circulation platform. Lab on A Chip, 2018, 18, 115-125.	3.1	119
591	Social Learning of Prescribing Behavior Can Promote Population Optimum of Antibiotic Use. Frontiers in Physics, 2018, 6, .	1.0	39
592	Utility of Integrated Analysis of Pharmacogenomics and Pharmacometabolomics in Early Phase Clinical Trial: A Case Study of a New Molecular Entity. Genomics and Informatics, 2018, 16, 52-58.	0.4	8
593	Phase 0, Including Microdosing Approaches: Applying the Three Rs and Increasing the Efficiency of Human Drug Development. ATLA Alternatives To Laboratory Animals, 2018, 46, 335-346.	0.7	17
594	Repurposing sertraline sensitizes nonâ€“small cell lung cancer cells to erlotinib by inducing autophagy. JCI Insight, 2018, 3, .	2.3	51
596	Financialized Corporations in a National Innovation System: The U.S. Pharmaceutical Industry. International Journal of Political Economy, 2018, 47, 281-316.	0.3	48
597	Establishment of an induced pluripotent stem cell model of Hirschsrpung disease, a congenital condition of the enteric nervous system, from a patient carrying a novel RET mutation. NeuroReport, 2018, 29, 975-980.	0.6	1
598	Factors Mediating Learning and Application of Computational Modeling by Life Scientists. , 2018, , .		5
599	Early Identification of Patentable Medical Innovations. , 2018, 2018, 4924-4926.		1
602	Mendelian Randomization Studies Promise to Shorten the Journey to FDAÂApproval. JACC Basic To Translational Science, 2018, 3, 690-703.	1.9	18
603	Academiaâ€“industry Cooperation in the Medical Field: Matching Opportunities in Japan. Clinical Therapeutics, 2018, 40, 1807-1812.	1.1	11

#	Article	IF	Citations
604	Is the Pace of Biomedical Innovation Slowing?. Perspectives in Biology and Medicine, 2018, 61, 584-593.	0.3	5
605	Net Present Value-Based Analyses of Products in Development by Pharmaceutical and Biotech Firms: NPV-Based Analyses of Biopharmaceutical Products. , 2018, , .		1
606	Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?. Risks, 2018, 6, 67.	1.3	2
607	Drivers of Orphan Drug Development. ACS Medicinal Chemistry Letters, 2018, 9, 962-964.	1.3	8
608	Management of Process Economyâ€"Case Studies. , 2018, , 1191-1223.		3
609	An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs. PLoS ONE, 2018, 13, e0204648.	1.1	14
610	Nanotoxicity in Cancer Research: Technical Protocols and Considerations for the Use of 3D Tumour Spheroids. , 2018, , .		1
611	The Who, What, and Why of Drug Discovery and Development. Trends in Pharmacological Sciences, 2018, 39, 848-852.	4.0	5
612	Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signalâ€seeking studies of targeted therapies for rare and neglected cancers. Medical Journal of Australia, 2018, 209, 354-355.	0.8	35
613	Roles of the RANKLâ€"RANK axis in antitumour immunity â€" implications for therapy. Nature Reviews Clinical Oncology, 2018, 15, 676-693.	12.5	77
614	Development of a biomimetic liver tumor-on-a-chip model based on decellularized liver matrix for toxicity testing. Lab on A Chip, 2018, 18, 3379-3392.	3.1	99
615	Future of Regulatory Safety Assessments. , 2018, , 1-24.		0
616	Elucidating the Dehydration Mechanism of Ondansetron Hydrochloride Dihydrate with a Crystal Structure. Crystal Growth and Design, 2018, 18, 6142-6149.	1.4	11
617	A novel anti-cancer role of Î²-apopicropodophyllin against non-small cell lung cancer cells. Toxicology and Applied Pharmacology, 2018, 357, 39-49.	1.3	9
618	Multi-parametric cell profiling with a CMOS quad-modality cellular interfacing array for label-free fully automated drug screening. Lab on A Chip, 2018, 18, 3037-3050.	3.1	31
619	Orphan Drugs and Their Impact on Pharmaceutical Development. Trends in Pharmacological Sciences, 2018, 39, 525-535.	4.0	43
620	Meta-Research on Oncology Trials: A Toolkit for Researchers with Limited Resources. Oncologist, 2018, 23, 1467-1473.	1.9	1
621	Microfluidic system for modelling 3D tumour invasion into surrounding stroma and drug screening. Biofabrication, 2018, 10, 034102.	3.7	35

#	Article	IF	Citations
622	An Industry Perspective on Dengue Drug Discovery and Development. Advances in Experimental Medicine and Biology, 2018, 1062, 333-353.	0.8	5
623	Recent advances in an organ-on-a-chip: biomarker analysis and applications. Analytical Methods, 2018, 10, 3122-3130.	1.3	27
624	Recommendations toward a human pathway-based approach to disease research. Drug Discovery Today, 2018, 23, 1824-1832.	3.2	23
625	In vivo MR in the drug pipeline. Journal of Magnetic Resonance, 2018, 292, 117-128.	1.2	4
627	Drug screening for human genetic diseases using iPSC models. Human Molecular Genetics, 2018, 27, R89-R98.	1.4	99
628	Immuno-detection by sequencing enables large-scale high-dimensional phenotyping in cells. Nature Communications, 2018, 9, 2384.	5.8	17
629	Deciphering cellular biological processes to clinical application: a new perspective for TÎ±1 treatment targeting multiple diseases. Expert Opinion on Biological Therapy, 2018, 18, 23-31.	1.4	11
630	A systematic approach to identify therapeutic effects of natural products based on human metabolite information. BMC Bioinformatics, 2018, 19, 205.	1.2	7
632	Computational Methodologies in the Exploration of Marine Natural Product Leads. Marine Drugs, 2018, 16, 236.	2.2	70
633	Filling the drug discovery gap: is high-content screening the missing link?. Current Opinion in Pharmacology, 2018, 42, 40-45.	1.7	21
634	Rational Drug Design Using Integrative Structural Biology. Methods in Molecular Biology, 2018, 1824, 89-111.	0.4	1
635	Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline. Frontiers in Pharmacology, 2018, 9, 703.	1.6	78
636	Innovation: Key to Success in the Pharmaceutical Industry. , 2018, , 1-16.		1
637	Four Stages of Pharmaceutical Product Development. , 2018, , 637-668.		4
638	Developing the Transdisciplinary Aging Research Agenda: New Developments in Big Data. Current Aging Science, 2018, 11, 33-44.	0.4	12
639	Radiopharmaceutical enhancement by drug delivery systems: A review. Journal of Controlled Release, 2018, 287, 177-193.	4.8	27
640	Preformulation in Drug Research and Pharmaceutical Product Development. , 2018, , 1-55.		4
641	Big Data: Challenge and Opportunity for Translational and Industrial Research in Healthcare. Frontiers in Digital Humanities, 2018, 5, .	1.2	9

#	Article	IF	Citations
642	Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology. Frontiers in Medicine, 2018, 5, 6.	1.2	14
643	Changing Trends in Computational Drug Repositioning. Pharmaceuticals, 2018, 11, 57.	1.7	127
644	Electrohydrodynamic atomization and spray-drying for the production of pure drug nanocrystals and co-crystals. Advanced Drug Delivery Reviews, 2018, 131, 79-100.	6.6	47
645	The future(s) of open science. Social Studies of Science, 2018, 48, 171-203.	1.5	203
646	Academic medical centers as innovation ecosystems to address population â€“omics challenges in precision medicine. Journal of Translational Medicine, 2018, 16, 28.	1.8	19
647	Pathways of Metabolite-Related Damage to a Synthetic p53 Gene Exon 7 Oligonucleotide Using Magnetic Enzyme Bioreactor Beads and LCâ€“MS/MS Sequencing. Biochemistry, 2018, 57, 3883-3893.	1.2	7
649	Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes. Blood, 2018, 132, 501-509.	0.6	52
650	Microfluidic-based vascularized microphysiological systems. Lab on A Chip, 2018, 18, 2686-2709.	3.1	74
651	High-throughput Identification of Synergistic Drug Combinations by the Overlap² Method. Journal of Visualized Experiments, 2018, , .	0.2	4
652	Transcriptomic RNAseq drug screen in cerebrocortical cultures: toward novel neurogenetic disease therapies. Human Molecular Genetics, 2018, 27, 3206-3217.	1.4	11
653	Human Genetics of Obesity and Type 2 Diabetes Mellitus. Circulation Genomic and Precision Medicine, 2018, 11, e002090.	1.6	58
654	Why is Growth More Difficult to Achieve for Biopharmaceutical Latecomer Firms? Evidence from Taiwan. Science, Technology and Society, 2018, 23, 388-417.	1.1	2
655	Human-specific approaches to brain research for the 21st century: a South American perspective. Drug Discovery Today, 2018, 23, 1929-1935.	3.2	1
656	Deep Learning for Drug Discovery and Cancer Research: Automated Analysis of Vascularization Images. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2019, 16, 1029-1035.	1.9	38
657	Clinical Trials and Therapeutic Rationale for Drug Repurposing in Schizophrenia. ACS Chemical Neuroscience, 2019, 10, 58-78.	1.7	13
658	Chemoinformatics: From Chemical Art to Chemistry in Silico. , 2019, , 601-618.		5
659	Drivers and Barriers to Drug Discovery: Insights from a Cross-sectional Survey. Journal of Pharmaceutical Innovation, 2019, 14, 35-49.	1.1	1
660	How soon will digital endpoints become a cornerstone for future drug development?. Drug Discovery Today, 2019, 24, 16-19.	3.2	31

#	Article	IF	Citations
661	Identification of novel analgesics through a drug repurposing strategy. Pain Management, 2019, 9, 399-415.	0.7	7
662	Ligand potency â€“ an essential estimator for drug design: between intuition, misinterpretation and serendipity. Future Medicinal Chemistry, 2019, 11, 1827-1843.	1.1	1
663	Consortium-Based Open Innovation: Exploring a Unique and Optimal Model for Regional Biotechnology Industry. Creative Economy, 2019, , 141-171.	0.1	1
665	CDx, NGS and regulation: five perspectives from the Pistoia Alliance. Drug Discovery Today, 2019, 24, 2120-2125.	3.2	4
666	Permeability of Epithelial/Endothelial Barriers in Transwells and Microfluidic Bilayer Devices. Micromachines, 2019, 10, 533.	1.4	60
667	Towards an African Light Source. Biophysical Reviews, 2019, 11, 499-507.	1.5	12
668	Deep learning in drug discovery: opportunities, challenges and future prospects. Drug Discovery Today, 2019, 24, 2017-2032.	3.2	182
669	Learning from Deep Representations of Multiple Networks for Predicting Drugâ€“Target Interactions. Lecture Notes in Computer Science, 2019, , 151-161.	1.0	10
670	The Anticancer Drug Discovery Potential of Marine Invertebrates from Russian Pacific. Marine Drugs, 2019, 17, 474.	2.2	16
671	Animal to human translation: a systematic scoping review of reported concordance rates. Journal of Translational Medicine, 2019, 17, 223.	1.8	170
672	Artificial Intelligence for Clinical Trial Design. Trends in Pharmacological Sciences, 2019, 40, 577-591.	4.0	288
673	A review of computational drug repurposing. Translational and Clinical Pharmacology, 2019, 27, 59.	0.3	138
674	Fibrosis in tissue engineering and regenerative medicine: treat or trigger?. Advanced Drug Delivery Reviews, 2019, 146, 17-36.	6.6	16
675	The Role of Philanthropy in Biomedical Research: Giving Your Body and Soul. Rejuvenation Research, 2019, 22, 348-352.	0.9	0
676	Sensor-free and Sensor-based Heart-on-a-chip Platform: A Review of Design and Applications. Current Pharmaceutical Design, 2019, 24, 5375-5385.	0.9	11
677	Microgravity protein crystallization for drug development: a bold example of public sector entrepreneurship. Journal of Technology Transfer, 2019, 46, 1442.	2.5	4
678	Drug repurposing with network reinforcement. BMC Bioinformatics, 2019, 20, 383.	1.2	13
679	Endogenous productivity of demandâ€induced R&D: evidence from pharmaceuticals. RAND Journal of Economics, 2019, 50, 591-614.	1.3	6

#	Article	IF	Citations
680	Carlina curetum plant phytoconstituents, enzymes inhibitory and cytotoxic activity on cervical epithelial carcinoma and colon cancer cell lines. European Journal of Integrative Medicine, 2019, 30, 100933.	0.8	30
681	Developing RNA aptamers for potential treatment of neurological diseases. Future Medicinal Chemistry, 2019, 11, 551-565.	1.1	8
682	The Convergence of Stem Cell Technologies and Phenotypic Drug Discovery. Cell Chemical Biology, 2019, 26, 1050-1066.	2.5	31
683	Lakatos revisited: Innovation and â€˜Novel factsâ€™ as a foundational logic for the social sciences in an era of â€˜Post-truthâ€™ and pseudoscience. Cogent Business and Management, 2019, 6, .	1.3	2
684	On the Simulation of Organ-on-Chip Cell Processes. , 2019, , 313-341.		1
685	Healthcare innovation methodology: codifying the process of translating knowledge into better healthcare products, services, and procedures. Current Opinion in Biomedical Engineering, 2019, 11, 16-21.	1.8	2
686	Pharmaceutical crisis. , 2019, , 1-10.		0
687	Why Are New Drugs Expensive and How Can They Stay Affordable?. Handbook of Experimental Pharmacology, 2019, 260, 453-466.	0.9	5
688	Open Source Process Insights From â€˜Microbial Learning'. International Journal of Sociotechnology and Knowledge Development, 2019, 11, 1-15.	0.4	1
689	Development of Predictive Models for Identifying Potential S100A9 Inhibitors Based on Machine Learning Methods. Frontiers in Chemistry, 2019, 7, 779.	1.8	20
690	A Scaffoldâ€Diversity Synthesis of Biologically Intriguing Cyclic Sulfonamides. Chemistry - A European Journal, 2019, 25, 15498-15503.	1.7	28
691	The NIH microphysiological systems program: developing in vitro tools for safety and efficacy in drug development. Current Opinion in Pharmacology, 2019, 48, 146-154.	1.7	34
692	Applications of molecular networks in biomedicine. Biology Methods and Protocols, 2019, 4, bpz012.	1.0	6
693	3D Engineering of Ocular Tissues for Disease Modeling and Drug Testing. Advances in Experimental Medicine and Biology, 2019, 1186, 171-193.	0.8	11
696	EK-DRD: A Comprehensive Database for Drug Repositioning Inspired by Experimental Knowledge. Journal of Chemical Information and Modeling, 2019, 59, 3619-3624.	2.5	4
697	In silico drug repositioning: from large-scale transcriptome data to therapeutics. Archives of Pharmacal Research, 2019, 42, 879-889.	2.7	30
698	Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature. Cancers, 2019, 11, 1284.	1.7	90
699	Benchmarking network propagation methods for disease gene identification. PLoS Computational Biology, 2019, 15, e1007276.	1.5	30

#	Article	IF	Citations
700	Inequality in healthcare R&D outcomes: a model of process disruption. Development Southern Africa, 2019, 36, 874-888.	1.1	2
701	Intracellular cardiomyocytes potential recording by planar electrode array and fibroblasts co-culturing on multi-modal CMOS chip. Biosensors and Bioelectronics, 2019, 144, 111626.	5.3	27
702	Perspectives on new strategies for the identification and development of insecticide targets. Pesticide Biochemistry and Physiology, 2019, 161, 23-32.	1.6	23
703	The NCATS Pharmaceutical Collection: a 10-year update. Drug Discovery Today, 2019, 24, 2341-2349.	3.2	48
704	Encapsulation of florfenicol by in situ crystallization into novel alginate-Eudragit RSÂ® blended matrix for pH modulated release. Journal of Drug Delivery Science and Technology, 2019, 54, 101241.	1.4	11
705	Incorporating Pharmacogenomics in Drug Development. , 2019, , 81-101.		1
706	The impact of external innovation on new drug approvals: A retrospective analysis. International Journal of Pharmaceutics, 2019, 563, 273-281.	2.6	10
707	Translational mechanobiology: Designing synthetic hydrogel matrices for improved in vitro models and cell-based therapies. Acta Biomaterialia, 2019, 94, 97-111.	4.1	38
708	New designs in early clinical drug development. Annals of Oncology, 2019, 30, 1460-1465.	0.6	14
709	Comparative analysis of correlations of research and development indicators for rare diseases among Japan, the US, and Europe. Scientometrics, 2019, 120, 361-374.	1.6	0
710	Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets.. Expert Opinion on Therapeutic Targets, 2019, 23, 711-724.	1.5	7
711	Combined Scaffold Evaluation and Systemsâ€Level Transcriptomeâ€Based Analysis for Accelerated Lead Optimization Reveals Ribosomal Targeting Spirooxindole Cyclopropanes. ChemMedChem, 2019, 14, 1653-1661.	1.6	11
712	Using artificial intelligence methods to speed up drug discovery. Expert Opinion on Drug Discovery, 2019, 14, 769-777.	2.5	54
713	Are We Opening the Door to a New Era of Medicinal Chemistry or Being Collapsed to a Chemical Singularity?. Journal of Medicinal Chemistry, 2019, 62, 10026-10043.	2.9	52
714	Orthogonal Drug Pooling Enhances Phenotype-Based Discovery of Ocular Antiangiogenic Drugs in Zebrafish Larvae. Frontiers in Pharmacology, 2019, 10, 508.	1.6	9
717	Trends in the costs of drugs launched in the UK between 1981 and 2015: an analysis of the launch price of drugs in five disease areas. BMJ Open, 2019, 9, e027625.	0.8	8
718	Insights into the biology of fibrodysplasia ossificans progressiva using patient-derived induced pluripotent stem cells. Regenerative Therapy, 2019, 11, 25-30.	1.4	11
719	An Antifungal for Antidiuresis?. Journal of the American Society of Nephrology: JASN, 2019, 30, 717-718.	3.0	2

#	Article	IF	Citations
720	Functionalityâ€Independent DNA Encoding of Complex Natural Products. Angewandte Chemie - International Edition, 2019, 58, 9254-9261.	7.2	54
721	Functionalityâ€Independent DNA Encoding of Complex Natural Products. Angewandte Chemie, 2019, 131, 9355-9362.	1.6	18
722	Engineering Tissues from Induced Pluripotent Stem Cells. Tissue Engineering - Part A, 2019, 25, 707-710.	1.6	11
723	A Medicinal Chemistâ€™s Perspective on Transitioning from Industry to Academic Drug Discovery. ACS Medicinal Chemistry Letters, 2019, 10, 687-689.	1.3	5
724	Transcriptome Guided Drug Combination Suppresses Proliferation of Breast Cancer Cells. Bulletin of Experimental Biology and Medicine, 2019, 166, 656-660.	0.3	3
725	Using Human Genetics to Drive Drug Discovery: A Perspective. American Journal of Kidney Diseases, 2019, 74, 111-119.	2.1	7
726	Analysis of energy-related CO2 emissions in China's pharmaceutical industry and its driving forces. Journal of Cleaner Production, 2019, 223, 94-108.	4.6	42
727	From single drug targets to synergistic network pharmacology in ischemic stroke. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7129-7136.	3.3	132
728	In Silico Modeling of FDA-Approved Drugs for Discovery of Anti-Cancer Agents: A Drug-Repurposing Approach. , 2019, , 577-608.		6
729	Stalis : A Computational Method for Templateâ€Based Ab Initio Ligand Design. Journal of Computational Chemistry, 2019, 40, 1622-1632.	1.5	4
730	What role do pharmaceuticals play in the treatment of Peyronieâ€™s disease and is there a need for new emerging drugs?. Expert Opinion on Emerging Drugs, 2019, 24, 1-4.	1.0	8
731	Leveraging Big Data to Transform Drug Discovery. Methods in Molecular Biology, 2019, 1939, 91-118.	0.4	27
732	Organoid Models of Development and Disease Towards Therapy. Current Human Cell Research and Applications, 2019, , 149-168.	0.1	0
733	Natural products: An upcoming therapeutic approach to cancer. Food and Chemical Toxicology, 2019, 128, 240-255.	1.8	189
734	One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry. Journal of Health Economics, 2019, 65, 260-283.	1.3	8
735	The Impact of Chemical Biology on Drug Discovery. Israel Journal of Chemistry, 2019, 59, 29-36.	1.0	1
736	Accelerated drug discovery by rapid candidate drug identification. Drug Discovery Today, 2019, 24, 1237-1241.	3.2	22
737	Time-Resolved Systems Medicine Reveals Viral Infection-Modulating Host Targets. Systems Medicine (New Rochelle, N Y), 2019, 2, 1-9.	1.4	14

#	Article	IF	Citations
738	Application of Co-Amorphous Technology for Improving the Physicochemical Properties of Amorphous Formulations. Molecular Pharmaceutics, 2019, 16, 2142-2152.	2.3	32
739	Exploring new technologies in biomedical research. Drug Discovery Today, 2019, 24, 1242-1247.	3.2	16
740	Imaging metabotropic glutamate receptor system: Application of positron emission tomography technology in drug development. Medicinal Research Reviews, 2019, 39, 1892-1922.	5.0	12
741	Shadow pricing and the art of profiteering from outdated therapies. Nature Biotechnology, 2019, 37, 217-220.	9.4	5
742	Mind and machine in drug design. Nature Machine Intelligence, 2019, 1, 128-130.	8.3	45
743	Creating cell and animal models of human disease by genome editing using CRISPR/Cas9. Journal of Gene Medicine, 2019, 21, e3082.	1.4	36
744	Improving the odds of drug development success through human genomics: modelling study. Scientific Reports, 2019, 9, 18911.	1.6	112
745	Redefining the research hospital. Npj Digital Medicine, 2019, 2, 119.	5.7	6
746	DeepCPI: A Deep Learning-based Framework for Large-scale in silico Drug Screening. Genomics, Proteomics and Bioinformatics, 2019, 17, 478-495.	3.0	53
747	Upcoming technologies breaking the bottleneck of industrial innovation in life science/ healthcare field: World trends in developing microphysiological system. Drug Delivery System, 2019, 34, 236-242.	0.0	0
748	The assessment of efficient representation of drug features using deep learning for drug repositioning. BMC Bioinformatics, 2019, 20, 577.	1.2	16
749	Menagerie: A text-mining tool to support animal-human translation in neurodegeneration research. PLoS ONE, 2019, 14, e0226176.	1.1	9
750	Single Spheroid Metabolomics: Optimizing Sample Preparation of Three-Dimensional Multicellular Tumor Spheroids. Metabolites, 2019, 9, 304.	1.3	16
751	Systematically Prioritizing Candidates in Genome-Based Drug Repurposing. Assay and Drug Development Technologies, 2019, 17, 352-363.	0.6	12
752	ACID: a free tool for drug repurposing using consensus inverse docking strategy. Journal of Cheminformatics, 2019, 11, 73.	2.8	52
753	Lost in translation: the valley of death across preclinical and clinical divide â€“ identification of problems and overcoming obstacles. Translational Medicine Communications, 2019, 4, .	0.5	299
754	Tetrafluoroethylene-Propylene Elastomer for Fabrication of Microfluidic Organs-on-Chips Resistant to Drug Absorption. Micromachines, 2019, 10, 793.	1.4	42
755	Using Machine Learning To Inform Decisions in Drug Discovery: An Industry Perspective. ACS Symposium Series, 2019, , 81-101.	0.5	1

#	Article	IF	Citations
756	The Productivity of Drug Development: A Systematic Review. , 2019, , .		1
757	Opportunities for Artificial Intelligence in Advancing Precision Medicine. Current Genetic Medicine Reports, 2019, 7, 208-213.	1.9	52
758	Development of a Microfluidic Array to Study Drug Response in Breast Cancer. Molecules, 2019, 24, 4385.	1.7	9
759	Innovation in Oncology Drug Development. Journal of Oncology, 2019, 2019, 1-16.	0.6	10
760	A novel tissue-engineered 3D tumor model for anti-cancer drug discovery. Biofabrication, 2019, 11, 015004.	3.7	24
761	Lost medicines: a longer view of the pharmaceutical industry with the potential to reinvigorate discovery. Drug Discovery Today, 2019, 24, 382-389.	3.2	6
762	USA, Europe and Pharmerging Countries: A Panorama of Pharmaceutical Innovation. Lecture Notes in Management and Industrial Engineering, 2019, , 303-311.	0.3	0
763	Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs. Journal of Medicinal Chemistry, 2019, 62, 1701-1714.	2.9	286
764	Application of complex in vitro models (CIVMs) in drug discovery for safety testing and disease modeling. , 2019, , 121-158.		5
765	Pair Matcher (PaM): fast model-based optimization of treatment/case-control matches. Bioinformatics, 2019, 35, 2243-2250.	1.8	10
766	Bioelectronic Medicineâ€"Ethical Concerns. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a034363.	2.9	5
767	New Frontiers in Cardiovascular Research: Microfluidic Modeling of Cardiovascular Diseases and Applications for Hypertension Research. , 2019, , 293-302.		0
768	Providing a New Aniline Bioisostere through the Photochemical Production of 1-Aminonorbornanes. CheM, 2019, 5, 215-226.	5.8	58
769	Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today, 2019, 24, 773-780.	3.2	408
770	Critical perspectives on international pharmaceutical innovation. Critical Perspectives on International Business, 2019, 15, 68-86.	1.4	8
771	Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: An underestimated truth. Biomedicine and Pharmacotherapy, 2019, 111, 934-946.	2.5	100
772	Precision medicine review: rare driver mutations and their biophysical classification. Biophysical Reviews, 2019, 11, 5-19.	1.5	43
773	Innovation in oncology clinical trial design. Cancer Treatment Reviews, 2019, 74, 15-20.	3.4	41

#	Article	IF	Citations
774	Future of Regulatory Safety Assessments. , 2019, , 1-24.		0
775	A rapid method for post-antibiotic bacterial susceptibility testing. PLoS ONE, 2019, 14, e0210534.	1.1	22
776	Diversity of Bioactive Compounds and Their Therapeutic Potential. , 2019, , 15-34.		9
777	Indian Berries and Their Active Compounds. , 2019, , 179-201.		4
778	Evolution of commercially available compounds for HTS. Drug Discovery Today, 2019, 24, 390-402.	3.2	53
779	Academic Discovery of Anticancer Drugs: Historic and Future Perspectives. Annual Review of Cancer Biology, 2019, 3, 385-408.	2.3	17
780	Integrating Biological Networks for Drug Target Prediction and Prioritization. Methods in Molecular Biology, 2019, 1903, 203-218.	0.4	11
781	Drug repurposing: progress, challenges and recommendations. Nature Reviews Drug Discovery, 2019, 18, 41-58.	21.5	2,689
782	Machine learning for integrating data in biology and medicine: Principles, practice, and opportunities. Information Fusion, 2019, 50, 71-91.	11.7	340
783	Making the Case for Functional Proteomics. Methods in Molecular Biology, 2019, 1871, 1-40.	0.4	4
784	The application of positron emission tomography (PET) imaging in CNS drug development. Brain Imaging and Behavior, 2019, 13, 354-365.	1.1	32
785	Web-based drug repurposing tools: a survey. Briefings in Bioinformatics, 2019, 20, 299-316.	3.2	38
786	Open innovation and the effects of Crowdsourcing in a pharma ecosystem. Journal of Innovation & Knowledge, 2019, 4, 240-247.	7.3	27
787	Previously reported placebo-response-associated variants do not predict patient outcomes in inflammatory disease Phase III trial placebo arms. Genes and Immunity, 2019, 20, 172-179.	2.2	2
788	Approach for Multicriteria Equipment Redesign in Sterile Manufacturing of Biopharmaceuticals. Journal of Pharmaceutical Innovation, 2020, 15, 15-25.	1.1	4
789	Plant natural fragments, an innovative approach for drug discovery. Phytochemistry Reviews, 2020, 19, 1141-1156.	3.1	5
790	The relationship of industry structure to open innovation: cooperative value creation in pharmaceutical consortia. R and D Management, 2020, 50, 116-135.	3.0	25
791	Organotypic and Microphysiological Models of Liver, Gut, and Kidney for Studies of Drug Metabolism, Pharmacokinetics, and Toxicity. Chemical Research in Toxicology, 2020, 33, 38-60.	1.7	30

#	Article	IF	Citations
792	Research and development spending and technical efficiency: evidence from biotechnology and pharmaceutical sector. International Journal of Production Research, 2020, 58, 6170-6184.	4.9	11
793	Engineering inkjet bioprinting processes toward translational therapies. Biotechnology and Bioengineering, 2020, 117, 272-284.	1.7	82
794	The â€˜death of innovationâ€™ paradox, R&D and the scientific potential of crowdsourcing. African Journal of Science, Technology, Innovation and Development, 2020, 12, 141-150.	0.8	3
795	Moonshots for aging. Nutrition and Healthy Aging, 2020, 5, 239-246.	0.5	1
796	Small-Scale Panel Comprising Diverse Gene Family Targets To Evaluate Compound Promiscuity. Chemical Research in Toxicology, 2020, 33, 154-161.	1.7	9
797	Old wine in new bottles: Drug repurposing in oncology. European Journal of Pharmacology, 2020, 866, 172784.	1.7	61
798	CEO research orientation, organizational context, and innovation in the pharmaceutical industry. R and D Management, 2020, 50, 239-254.	3.0	12
799	What's Past Is Prologue: Clinical Pharmacology at the Intersection of Science, Policy, and Patients. Clinical Pharmacology and Therapeutics, 2020, 107, 33-36.	2.3	3
800	Pharmaceutical quality control laboratory digital twin â€“ A novel governance model for resource planning and scheduling. International Journal of Production Research, 2020, 58, 6553-6567.	4.9	27
801	3D cell culture models and organâ€onâ€aâ€chip: Meet separation science and mass spectrometry. Electrophoresis, 2020, 41, 56-64.	1.3	41
802	Key indicators of phase transition for clinical trials through machine learning. Drug Discovery Today, 2020, 25, 414-421.	3.2	26
803	ChemBioServer 2.0: an advanced web server for filtering, clustering and networking of chemical compounds facilitating both drug discovery and repurposing. Bioinformatics, 2020, 36, 2602-2604.	1.8	26
804	An industrial approach towards solid dosage development for first-in-human studies: Application of predictive science and lean principles. Drug Discovery Today, 2020, 25, 505-518.	3.2	19
805	Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery. British Journal of Cancer, 2020, 122, 735-744.	2.9	134
806	Precision medicine at the academic-industry interface. , 2020, , 545-560.		1
807	Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. Nature Reviews Drug Discovery, 2020, 19, 93-111.	21.5	190
808	Metastasis-on-a-chip mimicking the progression of kidney cancer in the liver for predicting treatment efficacy. Theranostics, 2020, 10, 300-311.	4.6	60
809	Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition. Applied Health Economics and Health Policy, 2020, 18, 357-362.	1.0	15

#	Article	IF	Citations
810	Innovation in pharmaceutical R&D: mapping the research landscape. Scientometrics, 2020, 125, 1801-1832.	1.6	11
811	The effects of p53 gene inactivation on mutant proteome expression in a human melanoma cell model. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129722.	1.1	4
812	Herbal and Natural Dietary Products: Upcoming Therapeutic Approach for Prevention and Treatment of Hepatocellular Carcinoma. Nutrition and Cancer, 2021, 73, 2130-2154.	0.9	19
813	Drug Repurposing in Neurological Disorders: Implications for Neurotherapy in Traumatic Brain Injury. Neuroscientist, 2021, 27, 620-649.	2.6	10
814	Expanding roles for academic entrepreneurship in drug discovery. Drug Discovery Today, 2020, 25, 1905-1909.	3.2	10
815	High-throughput approaches for precision medicine in high-grade serous ovarian cancer. Journal of Hematology and Oncology, 2020, 13, 134.	6.9	36
816	Network Controllability-Based Prioritization of Candidates for SARS-CoV-2 Drug Repositioning. Viruses, 2020, 12, 1087.	1.5	3
817	Drug deliveryâ€"the increasing momentum. Drug Delivery and Translational Research, 2020, 10, 1888-1894.	3.0	4
818	Strict conformational demands of RNA cleavage in bulge-loops created by peptidyl-oligonucleotide conjugates. Nucleic Acids Research, 2020, 48, 10662-10679.	6.5	7
819	Guiding Conventional Proteinâ€"Ligand Docking Software with Convolutional Neural Networks. Journal of Chemical Information and Modeling, 2020, 60, 4594-4602.	2.5	15
820	Stem cells in natural product and medicinal plant drug discoveryâ€"An overview of new screening approaches. Biomedicine and Pharmacotherapy, 2020, 131, 110730.	2.5	9
821	Bioactive natural derivatives of phthalate ester. Critical Reviews in Biotechnology, 2020, 40, 913-929.	5.1	23
822	Fabrication of Hollow Structures in Photodegradable Hydrogels Using a Multi-Photon Excitation Process for Blood Vessel Tissue Engineering. Micromachines, 2020, 11, 679.	1.4	6
823	Molecular modelling of mebendazole polymorphs as a potential colchicine binding site inhibitor. New Journal of Chemistry, 2020, 44, 13990-13996.	1.4	54
824	Impact of Research and Development Strategy on Sustainable Growth in Multinational Pharmaceutical Companies. Sustainability, 2020, 12, 5358.	1.6	10
825	Repositioning of Anthelmintic Drugs for the Treatment of Cancers of the Digestive System. International Journal of Molecular Sciences, 2020, 21, 4957.	1.8	31
826	The development and use of facial grimace scales for pain measurement in animals. Neuroscience and Biobehavioral Reviews, 2020, 116, 480-493.	2.9	81
827	Nanomedicine beyond tumor passive targeting: what next?. Nanomedicine, 2020, 15, 1819-1822.	1.7	11

#	Article	IF	Citations
828	Optimization of Tree Ensembles. Operations Research, 2020, 68, 1605-1624.	1.2	39
829	Innovations in Metastatic Brain Tumor Treatment. , 2020, , .		1
830	Current Challenges and Opportunities in Designing Proteinâ€“Protein Interaction Targeted Drugs . Advances and Applications in Bioinformatics and Chemistry, 2020, Volume 13, 11-25.	1.6	34
831	How companies respond to growing research costs: cost control or value creation. International Journal of Technology Management, 2020, 82, 1.	0.2	5
832	Mechanistic Understanding From Molecular Dynamics Simulation in Pharmaceutical Research 1: Drug Delivery. Frontiers in Molecular Biosciences, 2020, 7, 604770.	1.6	54
833	Drug Repurposing Approaches to Combating Viral Infections. Journal of Clinical Medicine, 2020, 9, 3777.	1.0	23
834	Assembling the Puzzle of Taxifolin Polymorphism. Molecules, 2020, 25, 5437.	1.7	12
835	Mathematical formulation and parametric analysis of in vitro cell models in microfluidic devices: application to different stages of glioblastoma evolution. Scientific Reports, 2020, 10, 21193.	1.6	17
836	Drug Repurposing and Orphan Disease Therapeutics. , 0, , .		11
837	Therapeutic Drug Development and Human Clinical Trials. , 2020, , 339-358.		1
838	Reprogramming of antibiotics to combat antimicrobial resistance. Archiv Der Pharmazie, 2020, 353, e2000168.	2.1	15
839	â€œPulling the Plug:â€•Time Allocation between Drug Discovery and Development Projects. Production and Operations Management, 2020, 29, 2851-2876.	2.1	5
841	Integrated Array Chip for High-Throughput Screening of Species Differences in Metabolism. Analytical Chemistry, 2020, 92, 11696-11704.	3.2	10
842	Network and Systems Medicine: Position Paper of the European Collaboration on Science and Technology Action on Open Multiscale Systems Medicine. Network and Systems Medicine, 2020, 3, 67-90.	2.7	18
843	From Animal Poisons and Venoms to Medicines: Achievements, Challenges and Perspectives in Drug Discovery. Frontiers in Pharmacology, 2020, 11, 1132.	1.6	152
844	Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine . Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 531-542.	0.4	9
845	Strategic Patenting by Pharmaceutical Companies â€“ Should Competition Law Intervene?. IIC International Review of Intellectual Property and Competition Law, 2020, 51, 1062-1085.	0.3	19
846	Developing Collaborative Platforms to Advance Neurotechnology and Its Translation. Neuron, 2020, 108, 286-301.	3.8	29

#	Article	IF	Citations
847	Patient-Derived Xenograft vs. Organoids: A Preliminary Analysis of Cancer Research Output, Funding and Human Health Impact in 2014â€“2019. Animals, 2020, 10, 1923.	1.0	12
848	Investigating Core Signaling Pathways of Hepatitis B Virus Pathogenesis for Biomarkers Identification and Drug Discovery via Systems Biology and Deep Learning Method. Biomedicines, 2020, 8, 320.	1.4	5
849	Assessment of Tic Severity. , 2020, , 28-36.		0
850	Critical Analysis of Non-Thermal Plasma-Driven Modulation of Immune Cells from Clinical Perspective. International Journal of Molecular Sciences, 2020, 21, 6226.	1.8	17
851	Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak. Viruses, 2020, 12, 1058.	1.5	81
852	Introduction: The Long and Winding Road to Tourette Syndrome. , 2020, , 1-8.		0
853	Second-Generation Anti-dopaminergic Medications. , 2020, , 56-87.		0
854	Alpha-2 Adrenergic Medications. , 2020, , 88-98.		0
857	Computational Drug Repositioning: Current Progress and Challenges. Applied Sciences (Switzerland), 2020, 10, 5076.	1.3	24
858	On the Clinical Pharmacology of Reactive Oxygen Species. Pharmacological Reviews, 2020, 72, 801-828.	7.1	70
859	Guidelines Based on Systematic Literature Review and Meta-analysis. , 2020, , 127-145.		0
860	Phase 0/microdosing approaches: time for mainstream application in drug development?. Nature Reviews Drug Discovery, 2020, 19, 801-818.	21.5	55
861	Evaluation and Differential Diagnosis of Tics and Related Disorders. , 2020, , 9-27.		1
862	First-Generation Anti-dopaminergic Medications. , 2020, , 37-55.		0
863	Other Tic-Suppressing Medications. , 2020, , 99-126.		0
864	Guidelines Based on Expert Survey and Consensus. , 2020, , 146-149.		0
865	A Triple Helix systems perspective of UK drug discovery and development: A systematic review of REF impact case studies. Industry and Higher Education, 2021, 35, 650-666.	1.4	3
866	Enantiomeric Resolution and Absolute Configuration of a Chiral Î´-Lactam, Useful Intermediate for the Synthesis of Bioactive Compounds. Molecules, 2020, 25, 6023.	1.7	4

#	Article	IF	Citations
867	Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats. Journal of Inflammation Research, 2020, Volume 13, 1185-1205.	1.6	24
868	Tree-Based QSAR Model for Drug Repurposing in the Discovery of New Antibacterial Compounds against Escherichia coli. Pharmaceuticals, 2020, 13, 431.	1.7	10
869	Drug Repurposing in Neurological Diseases: Opportunities and Challenges. , 0, , .		2
870	Clinical pharmacology applications in clinical drug development and clinical care: A focus on Saudi Arabia. Saudi Pharmaceutical Journal, 2020, 28, 1217-1227.	1.2	9
871	Whole-Cell Phenotypic Screening of Medicines for Malaria Venture Pathogen Box Identifies Specific Inhibitors of Plasmodium falciparum Late-Stage Development and Egress. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	10
872	The emerging role of computational design in peptide macrocycle drug discovery. Expert Opinion on Drug Discovery, 2020, 15, 833-852.	2.5	27
873	Repurposing strategies on pyridazinone-based series by pharmacophore- and structure-driven screening. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1137-1144.	2.5	6
874	Repurposing current therapeutics for treating COVID â€19: A vital role of prescription records data mining. Drug Development Research, 2020, 81, 777-781.	1.4	17
875	Are Ideas Getting Harder to Find?. American Economic Review, 2020, 110, 1104-1144.	4.0	330
876	Druggability and drug-likeness concepts in drug design: are biomodelling and predictive tools having their say?. Journal of Molecular Modeling, 2020, 26, 120.	0.8	45
877	GalaxySagittarius: Structure- and Similarity-Based Prediction of Protein Targets for Druglike Compounds. Journal of Chemical Information and Modeling, 2020, 60, 3246-3254.	2.5	27
878	Repurposing Fenamic Acid Drugs To Combat Multidrug-Resistant Neisseria gonorrhoeae. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	20
879	Evolving Outsourcing Landscape in Pharma R&D: Different Collaborative Models and Factors To Consider When Choosing a Contract Research Organization. Journal of Medicinal Chemistry, 2020, 63, 11362-11367.	2.9	13
880	Soft drugs: design principles, success stories, and future perspectives. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 645-650.	1.5	16
881	Identifying drugs with diseaseâ€modifying potential in Parkinson's disease using artificial intelligence and pharmacoepidemiology. Pharmacoepidemiology and Drug Safety, 2020, 29, 864-872.	0.9	22
882	Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs. Computational and Structural Biotechnology Journal, 2020, 18, 1043-1055.	1.9	44
883	The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. , 2020, 213, 107579.		62
884	Medicinal Chemists versus Machines Challenge: What Will It Take to Adopt and Advance Artificial Intelligence for Drug Discovery?. Journal of Chemical Information and Modeling, 2020, 60, 2657-2659.	2.5	7

#	Article	IF	Citations
885	Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D. MAbs, 2020, 12, 1754999.	2.6	41
886	Prof. Cristobal dos Remedios and the Sydney Heart Bank: enabling translatable heart failure research. Biophysical Reviews, 2020, 12, 783-784.	1.5	1
887	Enhancing Chemogenomics with Predictive Pharmacology. Journal of Medicinal Chemistry, 2020, 63, 12243-12255.	2.9	3
888	Enabling actuation and sensing in organs-on-chip using electroactive polymers. , 2020, , .		1
889	LigBuilder V3: A Multi-Target de novo Drug Design Approach. Frontiers in Chemistry, 2020, 8, 142.	1.8	46
890	Repurposing Clinical Drugs as AdoMetDC Inhibitors Using the SCAR Strategy. Frontiers in Pharmacology, 2020, 11, 248.	1.6	12
891	Drug Repurposing Strategy against Fungal Biofilms. Current Topics in Medicinal Chemistry, 2020, 20, 509-516.	1.0	5
892	Exploratory Analysis of iPSCS-Derived Neuronal Cells as Predictors of Diagnosis and Treatment of Alzheimer Disease. Brain Sciences, 2020, 10, 166.	1.1	12
893	Synthetic approaches toward small molecule libraries. , 2020, , 1-34.		3
894	A critical review of recent trends, and a future perspective of optical spectroscopy as PAT in biopharmaceutical downstream processing. Analytical and Bioanalytical Chemistry, 2020, 412, 2047-2064.	1.9	70
895	Multiobjective de novo drug design with recurrent neural networks and nondominated sorting. Journal of Cheminformatics, 2020, 12, 14.	2.8	50
896	Rediscovery of natural compounds acting via multitarget recognition and noncanonical pharmacodynamical actions. Drug Discovery Today, 2020, 25, 920-927.	3.2	9
897	Intermolecular [3+3] ring expansion of aziridines to dehydropiperi-dines through the intermediacy of aziridinium ylides. Nature Communications, 2020, 11, 1273.	5.8	25
898	COVER: conformational oversampling as data augmentation for molecules. Journal of Cheminformatics, 2020, 12, 18.	2.8	20
899	Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making. Frontiers in Pharmacology, 2020, 11, 43.	1.6	14
900	Partnerships for better neglected disease drug discovery and development: how have we fared?. Expert Opinion on Drug Discovery, 2020, 15, 531-537.	2.5	5
901	Grafting of 3D Bioprinting to In Vitro Drug Screening: A Review. Advanced Healthcare Materials, 2020, 9, e1901773.	3.9	63
902	Drug targets for COVID-19 therapeutics: Ongoing global efforts. Journal of Biosciences, 2020, 45, 1.	0.5	69

#	Article	IF	Citations
903	Antibacterial R&D at a Crossroads: Weâ€™ve Pushed as Hard as We Can â€¦ Now We Need to Start Pulling!. Clinical Infectious Diseases, 2021, 73, e4451-e4453.	2.9	11
904	Role of Digital Microfluidics in Enabling Access to Laboratory Automation and Making Biology Programmable. SLAS Technology, 2020, 25, 411-426.	1.0	16
905	Applications of artificial intelligence in drug delivery and pharmaceutical development. , 2020, , 85-116.		14
906	Using technology-enabled social prescriptions to disrupt healthcare. Journal of the Royal Society of Medicine, 2020, 113, 59-63.	1.1	5
908	Exploration of the correlation between GPCRs and drugs based on a learning to rank algorithm. Computers in Biology and Medicine, 2020, 119, 103660.	3.9	29
909	International Strategy for Sustainable Growth in Multinational Pharmaceutical Companies. Sustainability, 2020, 12, 867.	1.6	14
910	Getting Beyond the Toy Domain. Meditations on David Deamerâ€™s â€œAssembling Lifeâ€• Life, 2020, 10, 18.	1.1	8
911	Sprinkling the pixie dust: reflections on innovation and innovators in medicinal chemistry and drug discovery. Drug Discovery Today, 2020, 25, 599-609.	3.2	5
912	Expanding Tiny Earth to genomics: a bioinformatics approach for an undergraduate class to characterize antagonistic strains. FEMS Microbiology Letters, 2020, 367, .	0.7	16
913	Bedload transport: a walk between randomness and determinism. Part 2. Challenges and prospects. Journal of Hydraulic Research/De Recherches Hydrauliques, 2020, 58, 18-33.	0.7	53
914	Electronic Health Records for Drug Repurposing: Current Status, Challenges, and Future Directions. Clinical Pharmacology and Therapeutics, 2020, 107, 712-714.	2.3	19
915	Hard-threshold neural network-based prediction of organic synthetic outcomes. BMC Chemical Engineering, 2020, 2, .	3.4	1
916	Openness, innovation, and science policy in the age of data-driven medicine. Science and Public Policy, 2023, 50, 947-949.	1.2	0
917	Drug Repositioning for Alzheimerâ€™s Disease: Finding Hidden Clues in Old Drugs. Journal of Alzheimer's Disease, 2020, 74, 1013-1028.	1.2	31
918	Screening of Natural Products and Approved Oncology Drug Libraries for Activity against Clostridioides difficile. Scientific Reports, 2020, 10, 5966.	1.6	9
919	Executable cancer models: successes and challenges. Nature Reviews Cancer, 2020, 20, 343-354.	12.8	43
920	Machine learningâ€driven protein engineering: a case study in computational drug discovery. Engineering Biology, 2020, 4, 7-9.	0.8	3
921	Drug repositioning: a brief overview. Journal of Pharmacy and Pharmacology, 2020, 72, 1145-1151.	1.2	185

#	Article	IF	Citations
922	A compound attributes-based predictive model for drug induced liver injury in humans. PLoS ONE, 2020, 15, e0231252.	1.1	4
923	The endless frontier? The recent increase of R&D productivity in pharmaceuticals. Journal of Translational Medicine, 2020, 18, 162.	1.8	42
924	On the Role of Artificial Intelligence in Genomics to Enhance Precision Medicine . Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 105-119.	0.4	10
925	Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions. Small Business Economics, 2021, 57, 603-634.	4.4	2
926	RNA knockdown by synthetic peptidyl-oligonucleotide ribonucleases: behavior of recognition and cleavage elements under physiological conditions. Journal of Biomolecular Structure and Dynamics, 2021, 39, 2555-2574.	2.0	3
927	Drug-pathway association prediction: from experimental results to computational models. Briefings in Bioinformatics, 2021, 22, .	3.2	30
928	Pharmaceutical drug development: high drug prices and the hidden role of public funding. Biologia Futura, 2021, 72, 129-138.	0.6	4
929	Structure-based drug repositioning: Potential and limits. Seminars in Cancer Biology, 2021, 68, 192-198.	4.3	26
930	Sources of innovation for new medicines: questions of sustainability. Drug Discovery Today, 2021, 26, 240-247.	3.2	10
931	Adaptive one-class Gaussian processes allow accurate prioritization of oncology drug targets. Bioinformatics, 2021, 37, 1420-1427.	1.8	2
932	How to Design AI-Driven Clinical Trials in Nuclear Medicine. Seminars in Nuclear Medicine, 2021, 51, 112-119.	2.5	17
933	Fenoterol and dobutamine as SARS-CoV-2 main protease inhibitors: AÂvirtual screening study. Journal of Molecular Structure, 2021, 1228, 129449.	1.8	10
934	Sex differences in the neurochemistry of frontal cortex: Impact of early life stress. Journal of Neurochemistry, 2021, 157, 963-981.	2.1	26
935	Clinical trial monitoring effectiveness: Remote risk-based monitoring versus on-site monitoring with 100% source data verification. Clinical Trials, 2021, 18, 158-167.	0.7	8
936	Time to Get Turned on by Chemical Biology. ChemBioChem, 2021, 22, 814-817.	1.3	3
937	Using artificial intelligence to identify antiâ€hypertensives as possible disease modifying agents in Parkinson's disease. Pharmacoepidemiology and Drug Safety, 2021, 30, 201-209.	0.9	11
938	Exploring the dynamics of novelty production through exaptation: a historical analysis of coal tar-based innovations. Research Policy, 2021, 50, 104171.	3.3	17
939	Challenges and prospects in Chinese pharmaceutical regulatory environment. Journal of Generic Medicines, 2021, 17, 106-114.	0.0	1

#	Article	IF	Citations
940	Organs-on-chips: into the next decade. Nature Reviews Drug Discovery, 2021, 20, 345-361.	21.5	459
941	Challenges of Psychiatry Drug Development and the Role of Human Pharmacology Models in Early Developmentâ€"A Drug Developer's Perspective. Frontiers in Psychiatry, 2020, 11, 562660.	1.3	9
942	Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis. Health Economics Review, 2021, 11, 4.	0.8	12
945	SPP-CPI: Predicting Compoundâ€"Protein Interactions Based On Neural Networks. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2022, 19, 40-47.	1.9	4
946	Drugmonizome and Drugmonizome-ML: integration and abstraction of small molecule attributes for drug enrichment analysis and machine learning. Database: the Journal of Biological Databases and Curation, 2021, 2021, .	1.4	19
947	Systems Medicine Design based on Systems Biology Approaches and Deep Neural Network for Gastric Cancer. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2022, 19, 3019-3031.	1.9	0
948	Early Development of Erenumab for Migraine Prophylaxis. , 2021, , 245-255.		1
949	Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century. Mini-Reviews in Medicinal Chemistry, 2021, 21, 3-9.	1.1	6
950	MGATRx: Discovering Drug Repositioning Candidates Using Multi-View Graph Attention. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2022, 19, 2596-2604.	1.9	6
951	From Homology Modeling to the Hit Identification and Drug Repurposing: A Structure-Based Approach in the Discovery of Novel Potential Anti-Obesity Compounds. Methods in Molecular Biology, 2021, 2266, 263-277.	0.4	3
952	Comparing long-term value creation after biotech and non-biotech IPOs, 1997â€"2016. PLoS ONE, 2021, 16, e0243813.	1.1	2
953	Overcoming Sparseness of Biomedical Networks to Identify Drug Repositioning Candidates. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2022, 19, 2377-2384.	1.9	3
954	Innovator, Entrepreneur, Leader: The Tripartite Drug Discovery Neuroscientist. , 2021, , 3-22.		0
955	Selecting Approaches for Hit Identification and Increasing Options by Building the Efficient Discovery of Actionable Chemical Matter from DNA-Encoded Libraries. SLAS Discovery, 2021, 26, 263-280.	1.4	24
956	The Integration of Artificial Intelligence in Drug Discovery and Development. International Journal of Digital Health, 2021, 1, 5.	0.4	2
957	Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Research, 2021, 6, 16.	0.9	90
958	Analysis of physicochemical properties of proteinâ€"protein interaction modulators suggests stronger alignment with the â€œrule of fiveâ€• RSC Medicinal Chemistry, 2021, 12, 1731-1749.	1.7	13
959	Network Analysis in Systems Biology. , 2021, , 434-445.		0

#	Article	IF	Citations
960	â€œOrgan-on-a-chipâ€•based physiologically relevant pharmacokinetic models. , 2021, , 643-673.		2
961	Imaging therapeutic peptide transport across intestinal barriers. RSC Chemical Biology, 2021, 2, 1115-1143.	2.0	10
962	Monobodies as tool biologics for accelerating target validation and druggable site discovery. RSC Medicinal Chemistry, 2021, 12, 1839-1853.	1.7	10
963	The Golden Spice Turmeric (<i>Curcuma longa</i>) and Its Feasible Benefits in Prospering Human Healthâ€”A Review. American Journal of Plant Sciences, 2021, 12, 455-475.	0.3	20
964	Computational drug repurposing: A review in modern application. AIP Conference Proceedings, 2021, , .	0.3	1
965	Oral biopharmaceutics tools: recent progress from partnership through the Pharmaceutical Education and Research with Regulatory Links collaboration. Journal of Pharmacy and Pharmacology, 2021, 73, 437-446.	1.2	8
966	Microfluidic and Organ-on-a-Chip Approaches to Investigate Cellular and Microenvironmental Contributions to Cardiovascular Function and Pathology. Frontiers in Bioengineering and Biotechnology, 2021, 9, 624435.	2.0	25
967	A Decade of FDA-Approved Drugs (2010â€“2019): Trends and Future Directions. Journal of Medicinal Chemistry, 2021, 64, 2312-2338.	2.9	145
968	Supporting Computational Apprenticeship Through Educational and Software Infrastructure: A Case Study in aÂMathematical Oncology Research Lab. Primus, 2022, 32, 446-467.	0.3	0
969	Advanced control strategies for bioprocess chromatography: Challenges and opportunities for intensified processes and next generation products. Journal of Chromatography A, 2021, 1639, 461914.	1.8	21
970	Fragmentâ€Based Nuclear Magnetic Resonance Screen against a Regulator of G Protein Signaling Identifies a Binding â€œHot Spotâ€• ChemBioChem, 2021, 22, 1609-1620.	1.3	2
971	Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies. Immunopharmacology and Immunotoxicology, 2021, 43, 105-125.	1.1	24
972	Chemically Defined Xeno- and Serum-Free Cell Culture Medium to Grow Human Adipose Stem Cells. Cells, 2021, 10, 466.	1.8	10
973	The role of patent expiration in acquisition decision and target selection in the pharmaceutical industry. R and D Management, 2021, 51, 521.	3.0	0
974	Fresh Molecular Concepts to Extend the Lifetimes of Old Antimicrobial Drugs. Chemical Record, 2021, 21, 631-645.	2.9	2
975	Readying students for careers in industry: A guided inquiry activity to prepare students for success in biotechnology and pharmaceutical industry positions. Biochemistry and Molecular Biology Education, 2021, 49, 407-415.	0.5	3
976	SÃ©curitÃ© sanitaire sous dÃ©pendance. Revue De La RÃ©gulation, 2021, , .	0.1	0
977	Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Research, 2021, 6, 16.	0.9	48

#	Article	IF	Citations
978	Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma. Pharmaceuticals, 2021, 14, 280.	1.7	11
979	Computationally designed peptide macrocycle inhibitors of New Delhi metallo-Î²-lactamase 1. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	41
980	Emerging Pharmaceutical Companies from China, India, and Brazil. , 2021, , 222-255.		0
981	Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics. Scientific Reports, 2021, 11, 6725.	1.6	25
982	On the role of Brain Imaging in drug development for psychiatry. Current Clinical Pharmacology, 2021, 16, 46-71.	0.2	0
983	Alternative strategies in cardiac preclinical research and new clinical trial formats. Cardiovascular Research, 2022, 118, 746-762.	1.8	13
985	Systems Medicine Design for Triple-Negative Breast Cancer and Non-Triple-Negative Breast Cancer Based on Systems Identification and Carcinogenic Mechanisms. International Journal of Molecular Sciences, 2021, 22, 3083.	1.8	1
986	Tackling the reproducibility problem to empower translation of preclinical academic drug discovery: is there an answer?. Expert Opinion on Drug Discovery, 2021, 16, 595-600.	2.5	1
987	Can Financial Economics Cure Cancer?. Atlantic Economic Journal, 2021, 49, 3-21.	0.3	4
988	Data-driven molecular design for discovery and synthesis of novel ligands: a case study on SARS-CoV-2. Machine Learning: Science and Technology, 2021, 2, 025024.	2.4	16
989	Generation of Vascular Smooth Muscle Cells From Induced Pluripotent Stem Cells. Circulation Research, 2021, 128, 670-686.	2.0	35
990	Generating Theory by Abduction. Academy of Management Review, 2021, 46, 684-701.	7.4	185
992	Non-ulcerogenic pyrazolyl 2-hydroxychalcones and pyrazolylpyrazolines derived from naturally existing furochromone (khellin): semi-synthesis, docking study and anti-inflammatory activity. Natural Product Research, 2022, 36, 2486-2494.	1.0	2
993	Excipient-Free Pure Drug Nanoparticles Fabricated by Microfluidic Hydrodynamic Focusing. Pharmaceutics, 2021, 13, 529.	2.0	8
994	Drug Repurposing in Oncology: Current Evidence and Future Direction. Current Medicinal Chemistry, 2021, 28, 2175-2194.	1.2	6
995	PaccMannRL: De novo generation of hit-like anticancer molecules from transcriptomic data via reinforcement learning. IScience, 2021, 24, 102269.	1.9	42
996	Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy. Pharmaceuticals, 2021, 14, 372.	1.7	21
998	Use of artificial intelligence to enhance phenotypic drug discovery. Drug Discovery Today, 2021, 26, 887-901.	3.2	30

#	Article	IF	Citations
999	Approval success rates of drug candidates based on target, action, modality, application, and their combinations. Clinical and Translational Science, 2021, 14, 1113-1122.	1.5	35
1001	Competition and R&D Financing: Evidence From the Biopharmaceutical Industry. Journal of Financial and Quantitative Analysis, 2022, 57, 1885-1928.	2.0	16
1002	Low-N protein engineering with data-efficient deep learning. Nature Methods, 2021, 18, 389-396.	9.0	212
1003	Multiscale Virtual Screening Optimization for Shotgun Drug Repurposing Using the CANDO Platform. Molecules, 2021, 26, 2581.	1.7	12
1004	Application of network link prediction in drug discovery. BMC Bioinformatics, 2021, 22, 187.	1.2	44
1005	Metformin treatment response is dependent on glucose growth conditions and metabolic phenotype in colorectal cancer cells. Scientific Reports, 2021, 11, 10487.	1.6	18
1006	Converging global crises are forcing the rapid adoption of disruptive changes in drug discovery. Drug Discovery Today, 2021, 26, 2489-2495.	3.2	1
1007	Automation and miniaturization: enabling tools for fast, highâ€throughput process development in integrated continuous biomanufacturing. Journal of Chemical Technology and Biotechnology, 2022, 97, 2365-2375.	1.6	22
1008	Functional and Material Properties in Nanocatalyst Design: A Data Handling and Sharing Problem. International Journal of Molecular Sciences, 2021, 22, 5176.	1.8	6
1009	Brief Overview of Approaches and Challenges in New Antibiotic Development: A Focus On Drug Repurposing. Frontiers in Cellular and Infection Microbiology, 2021, 11, 684515.	1.8	56
1010	Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics. Neuropsychopharmacology, 2021, 46, 1788-1801.	2.8	12
1011	Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury. Current Medicinal Chemistry, 2021, 28, 2369-2391.	1.2	15
1012	Introduction to the EQIPD quality system. ELife, 2021, 10, .	2.8	42
1013	The interplay between lipid and Aî² amyloid homeostasis in Alzheimerâ€™s Disease: risk factors and therapeutic opportunities. Chemistry and Physics of Lipids, 2021, 236, 105072.	1.5	16
1015	Anthelmintics for drug repurposing: Opportunities and challenges. Saudi Pharmaceutical Journal, 2021, 29, 434-445.	1.2	27
1016	KRAS and EGFR Mutations Differentially Alter ABC Drug Transporter Expression in Cisplatin-Resistant Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2021, 22, 5384.	1.8	9
1017	In vivo antidiabetic potential of standardized Gymnocarpos decandrus Forssk. Extract. Journal of Diabetes and Metabolic Disorders, 2021, 20, 1129-1135.	0.8	2
1018	Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa. ELife, 2021, 10, .	2.8	15

#	Article	IF	Citations
1019	Predicting Successes and Failures of Clinical Trials With Outer Productâ€“Based Convolutional Neural Network. Frontiers in Pharmacology, 2021, 12, 670670.	1.6	18
1021	Repurposing Drugs to Treat Heart and Brain Illness. Pharmaceuticals, 2021, 14, 573.	1.7	3
1022	Lipid membrane-based therapeutics and diagnostics. Archives of Biochemistry and Biophysics, 2021, 704, 108858.	1.4	4
1023	Scope of Mitigating Recession in Output of Indian Textile Industry through Productivity Growth: Evidence Using Nonparametric Data Envelopment Analysis. , 2021, , 183-203.		0
1025	Recent investigation on heterocycles with one nitrogen [piperidine, pyridine and quinoline], two nitrogen [1,3,4-thiadiazole and pyrazole] and three nitrogen [1,2,4-triazole]: a review. Journal of the Iranian Chemical Society, 2022, 19, 23-54.	1.2	10
1026	A comprehensive review on the application of artificial intelligence in drug discovery.. The Applied Biology & Chemistry Journal, 0, , 34-48.	0.0	1
1027	AI-based language models powering drug discovery and development. Drug Discovery Today, 2021, 26, 2593-2607.	3.2	48
1028	Lessons and insights from the global productivity slowdown: A research management agenda. African Journal of Science, Technology, Innovation and Development, 2022, 14, 1265-1273.	0.8	3
1029	Opportunities and challenges in translational science. Clinical and Translational Science, 2021, 14, 1629-1647.	1.5	59
1030	Network moduleâ€based drug repositioning for pulmonary arterial hypertension. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 994-1005.	1.3	10
1031	Improving Measures of Chemical Structural Similarity Using Machine Learning on Chemicalâ€“Genetic Interactions. Journal of Chemical Information and Modeling, 2021, 61, 4156-4172.	2.5	11
1032	Systematic risk identification and assessment using a new risk map in pharmaceutical R&D. Drug Discovery Today, 2021, 26, 2786-2793.	3.2	8
1033	De Novo Prediction of Drugâ€“Target Interactions Using Laplacian Regularized Schatten p-Norm Minimization. Journal of Computational Biology, 2021, 28, 660-673.	0.8	2
1034	Renewed interests in the discovery of bioactive actinomycete metabolites driven by emerging technologies. Journal of Applied Microbiology, 2022, 132, 59-77.	1.4	17
1035	AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer. Frontiers in Pharmacology, 2021, 12, 660313.	1.6	7
1036	Turmeric (Curcuma longa L.): Chemical Components and Their Effective Clinical Applications. Journal of the Turkish Chemical Society, Section A: Chemistry, 2021, 8, 883-898.	0.4	7
1037	R&D efficiency of leading pharmaceutical companies â€“ A 20-year analysis. Drug Discovery Today, 2021, 26, 1784-1789.	3.2	25
1038	Semisynthetic Macrocyclic Lipo-lanthipeptides Display Antimicrobial Activity Against Bacterial Pathogens. ACS Synthetic Biology, 2021, 10, 1980-1991.	1.9	12

#	Article	IF	Citations
1039	Predicting drug approvals: The Novartis data science and artificial intelligence challenge. Patterns, 2021, 2, 100312.	3.1	17
1040	Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems. Therapeutics and Clinical Risk Management, 2021, Volume 17, 877-887.	0.9	1
1041	A CMOS 21 952-Pixel Multi-Modal Cell-Based Biosensor With Four-Point Impedance Sensing for Holistic Cellular Characterization. IEEE Journal of Solid-State Circuits, 2021, 56, 2438-2451.	3.5	10
1042	Identification of new target proteins of a Urotensin-II receptor antagonist using transcriptome-based drug repositioning approach. Scientific Reports, 2021, 11, 17138.	1.6	4
1043	Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates. Cancers, 2021, 13, 3946.	1.7	15
1044	1- and 2-Azetines via Visible Light-Mediated [2 + 2]-Cycloadditions of Alkynes and Oximes. Journal of the American Chemical Society, 2021, 143, 16235-16242.	6.6	30
1045	Exploring the Current Practices, Costs and Benefits of FAIR Implementation in Pharmaceutical Research and Development: A Qualitative Interview Study. Data Intelligence, 2021, 3, 507-527.	0.8	9
1046	The DMS must rapidly reshape its systems to cultivate and sustain innovation and the implementation of new digital technologies. BMJ Military Health, 2023, 169, 385-387.	0.4	2
1047	Digital Endpoints: Definition, Benefits, and Current Barriers in Accelerating Development and Adoption. Digital Biomarkers, 2021, 5, 216-223.	2.2	21
1048	Organizing Uncertainty as an Asset in Creative Collaboration: A Comparison of the Music and Pharmaceutical Industries. Research in the Sociology of Organizations, 2021, , 115-136.	0.5	1
1049	Challenging the pipeline. Stem Cell Reports, 2021, 16, 2033-2037.	2.3	8
1050	Theoretical Studies on the Molecular Properties, Toxicity, and Biological Efficacy of 21 New Chemical Entities. ACS Omega, 2021, 6, 24891-24901.	1.6	44
1051	Predicting and Understanding Non-Covalent Interactions Using Novel Forms of Symmetry-Adapted Perturbation Theory. Accounts of Chemical Research, 2021, 54, 3679-3690.	7.6	22
1052	Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARSâ€CoVâ€2: A Combinedin silicoandinâ€...vitroStudy. Molecular Informatics, 2022, 41, e2100062.	1.4	9
1053	Drug Repurposing for Targeting Acute Leukemia With KMT2A (MLL)â€"Gene Rearrangements. Frontiers in Pharmacology, 2021, 12, 741413.	1.6	8
1054	Effects of Naodesheng tablets on amyloid beta-induced dysfunction: A traditional Chinese herbal formula with novel therapeutic potential in Alzheimer's disease revealed by systems pharmacology. Biomedicine and Pharmacotherapy, 2021, 141, 111916.	2.5	5
1055	Social media mining in drug developmentâ€"Fundamentals and use cases. Drug Discovery Today, 2021, 26, 2871-2880.	3.2	9
1056	Computational pharmaceutics - A new paradigm of drug delivery. Journal of Controlled Release, 2021, 338, 119-136.	4.8	75

#	Article	IF	Citations
1057	Growth contributions of technological change: Is there a burden of knowledge effect?. Technological Forecasting and Social Change, 2021, 172, 121076.	6.2	5
1058	RNA aptamers for AMPA receptors. Neuropharmacology, 2021, 199, 108761.	2.0	5
1059	Hybrids of 4-hydroxy derivatives of goniothalamin and piplartine bearing a diester or a 1,2,3-triazole linker as antiproliferative agents. Bioorganic Chemistry, 2021, 116, 105292.	2.0	2
1060	Searching for an ideal SERM: Mining tamoxifen structureâ€“activity relationships. Bioorganic and Medicinal Chemistry Letters, 2021, 52, 128383.	1.0	5
1061	Preclinical and clinical toxicity of immuno-oncology therapies and mitigation strategies. , 2022, , 499-513.		0
1062	Investigation and assessment of blockchain technology adoption in the pharmaceutical supply chain. Materials Today: Proceedings, 2021, 46, 10776-10780.	0.9	21
1063	Peptides and Peptidomimetics as Foundations for Drug Discovery. , 2021, , 1-7.		0
1064	Clinical Research and Regulatory Affairs. Advances in Medical Education, Research, and Ethics, 2021, , 160-184.	0.1	0
1065	High-throughput organ-on-chip platform with integrated programmable fluid flow and real-time sensing for complex tissue models in drug development workflows. Lab on A Chip, 2021, 21, 1454-1474.	3.1	107
1066	Magic bullets: Drug repositioning and drug combinations. , 2022, , 770-788.		2
1069	Discovery Formulations: Approaches and Practices in Early Preclinical Development. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 49-94.	0.2	8
1070	Pragmatic Trials and New Informatics Methods to Supplement or Replace Phase IV Trials. Computers in Health Care, 2020, , 199-213.	0.2	1
1071	Revisiting the Concept of Human Disease. Human Perspectives in Health Sciences and Technology, 2020, , 1-34.	0.2	3
1072	PaccMannRL: Designing Anticancer Drugs From Transcriptomic Data via Reinforcement Learning. Lecture Notes in Computer Science, 2020, , 231-233.	1.0	16
1073	Preclinical Studies to Enable First in Human Clinical Trials. , 2020, , 45-69.		1
1074	A Design of Experiment Approach to Optimize an Image Analysis Protocol for Drug Screening. , 2015, , 65-84.		4
1076	Innovative Health Technologies and Start-Ups Process in Healthcare Industry. , 2019, , 123-159.		1
1077	Biomedical Research in the 21st Century: Multiple Challenges in Resolving Reproducibility Issues. , 2018, , 307-353.		1

#	Article	IF	Citations
1079	The Pharmaceutical Industry and the Future of Drug Development. Issues in Environmental Science and Technology, 2015, , 1-33.	0.4	77
1091	Preventive healthcare policies in the US: solutions for disease management using Big Data Analytics. Journal of Big Data, 2020, 7, 38.	6.9	18
1092	Business Process Model of Continuous Improvement in Pharmaceutical Manufacturing. Kagaku Kogaku Ronbunshu, 2014, 40, 201-210.	0.1	3
1093	Identifying stroke therapeutics from preclinical models: A protocol for a novel application of network meta-analysis. F1000Research, 2019, 8, 11.	0.8	7
1094	Ideation and implementation of an open science drug discovery business model â€“ M4K Pharma. Wellcome Open Research, 2018, 3, 154.	0.9	19
1096	An open source pharma roadmap. PLoS Medicine, 2017, 14, e1002276.	3.9	26
1097	Ligand-Induced Protein Mobility in Complexes of Carbonic Anhydrase II and Benzenesulfonamides with Oligoglycine Chains. PLoS ONE, 2013, 8, e57629.	1.1	2
1098	Tracking 20 Years of Compound-to-Target Output from Literature and Patents. PLoS ONE, 2013, 8, e77142.	1.1	17
1099	Translational Science by Public Biotechnology Companies in the IPOâ€œClass of 2000â€• The Impact of Technological Maturity. PLoS ONE, 2013, 8, e82195.	1.1	6
1100	Achieving a â€œGrand Convergenceâ€•in Global Health: Modeling the Technical Inputs, Costs, and Impacts from 2016 to 2030. PLoS ONE, 2015, 10, e0140092.	1.1	24
1101	When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis. PLoS ONE, 2016, 11, e0147215.	1.1	202
1102	How Can Viral Dynamics Models Inform Endpoint Measures in Clinical Trials of Therapies for Acute Viral Infections?. PLoS ONE, 2016, 11, e0158237.	1.1	24
1103	The Researchersâ€™ View of Scientific Rigorâ€”Survey on the Conduct and Reporting of In Vivo Research. PLoS ONE, 2016, 11, e0165999.	1.1	53
1104	Timelines of translational science: From technology initiation to FDA approval. PLoS ONE, 2017, 12, e0177371.	1.1	43
1105	Animal testing and its alternatives â€“ the most important omics is economics. ALTEX: Alternatives To Animal Experimentation, 2018, 35, 275-305.	0.9	105
1106	In vitro testicular toxicity models: Opportunities for advancement via biomedical engineering techniques. ALTEX: Alternatives To Animal Experimentation, 2013, 30, 353-377.	0.9	26
1107	Case studies on computer-based identification of natural products as lead molecules. ChemistrySelect, 2020, 5, .	0.7	1
1108	Cancer megafunds with in silico and in vitro validation: accelerating cancer drug discovery via financial engineering without financial crisis. Oncotarget, 2016, 7, 57671-57678.	0.8	8

#	Article	IF	Citations
1109	Strategies for Skeletal Muscle Targeting in Drug Discovery. Current Pharmaceutical Design, 2015, 21, 1327-1336.	0.9	19
1110	Cancer-on-a-chip for Drug Screening. Current Pharmaceutical Design, 2019, 24, 5407-5418.	0.9	10
1111	TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation. Current Drug Targets, 2015, 16, 393-408.	1.0	28
1112	Toward Small-Molecule Inhibition of Proteinâ€“Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions. Current Topics in Medicinal Chemistry, 2018, 18, 674-699.	1.0	69
1113	Parallelization of Molecular Docking: A Review. Current Topics in Medicinal Chemistry, 2018, 18, 1015-1028.	1.0	53
1114	From Target Identification to Drug Development in Space: Using the Microgravity Assist. Current Drug Discovery Technologies, 2020, 17, 45-56.	0.6	19
1115	Data Validation and Verification Using Blockchain in a Clinical Trial for Breast Cancer: Regulatory Sandbox. Journal of Medical Internet Research, 2020, 22, e18938.	2.1	28
1116	An integrative machine learning approach for prediction of toxicity-related drug safety. Life Science Alliance, 2018, 1, e201800098.	1.3	44
1117	Citizen Science and Biomedical Research: Implications for Bioethics Theory and Practice. Informing Science, 0, 19, 325-343.	0.0	6
1118	Assessment of the Antitumor Potential of Umbelliprenin, a Naturally Occurring Sesquiterpene Coumarin. Biomedicines, 2020, 8, 126.	1.4	14
1119	Analysis of the Parametric Correlation in Mathematical Modeling of In Vitro Glioblastoma Evolution Using Copulas. Mathematics, 2021, 9, 27.	1.1	1
1120	Profits, Innovation and Financialization in the Insulin Industry. , 2020, , 1-36.		2
1121	Government as the First Investor in Biopharmaceutical Innovation: Evidence From New Drug Approvals 2010â€“2019. , 2020, , 1-72.		6
1122	Modeling neuromuscular junctions in vitro: A review of the current progress employing human induced pluripotent stem cells. AIMS Cell and Tissue Engineering, 2018, 2, 91-118.	0.4	5
1123	Drug Discovery. Advances in Medical Technologies and Clinical Practice Book Series, 2019, , 1-46.	0.3	1
1124	The Probabilistic Innovation Field of Scientific Enquiry. International Journal of Sociotechnology and Knowledge Development, 2017, 9, 56-72.	0.4	3
1125	The Necessity of Holistic View on Nanomedicine. Journal of Nanomedicine & Nanotechnology, 2017, 08, .	1.1	3
1126	The Ethical Implications for Humans in Light of the Poor Predictive Value of Animal Models. International Journal of Clinical Medicine, 2014, 05, 966-1005.	0.1	4

#	Article	IF	Citations
1127	An Integrative Approach for Discovery of New Uses of Existing Drugs. Data Science Journal, 2015, 14, 9.	0.6	3
1129	Measuring Exaptation in the Pharmaceutical Industry. Proceedings - Academy of Management, 2015, 2015, 17085.	0.0	4
1130	A Guide to Time lag and Time lag Shortening Strategies in Oncology-Based Drug Development. Journal of Commercial Biotechnology, 2017, 23, 75-81.	0.2	3
1131	Personalization of medical treatments in oncology: time for rethinking the disease concept to improve individual outcomes. EPMA Journal, 2021, 12, 545-558.	3.3	11
1132	Facilitating Antiviral Drug Discovery Using Genetic and Evolutionary Knowledge. Viruses, 2021, 13, 2117.	1.5	3
1133	Recent applications of quantitative systems pharmacology and machine learning models across diseases. Journal of Pharmacokinetics and Pharmacodynamics, 2022, 49, 19-37.	0.8	22
1134	Trends of pharmaceutical corporationsâ€™ external innovation strategies: An inverse sigmoid curve. Technology in Society, 2021, 67, 101785.	4.8	6
1135	Marketing Im Gesundheitssektor. SSRN Electronic Journal, 0, , .	0.4	0
1136	Novel New Drug Approvals in 2011: A Succinct Analysis of Drug Discovery Trends in the United States. International Journal of Pharmaceutical Sciences and Nanotechnology, 2012, 5, 1661-1665.	0.0	3
1137	Nanomedicine: Economic Prospect and Public Safety. Journal of Developing Drugs, 2013, 02, .	0.9	0
1138	Wandel und Herausforderung â€“ die pharmazeutische Industrie. , 2013, , 1-52.		2
1139	New Drugs of 2012: A Concise Overview of the NMEs and Trends for Innovative Brand Market in the United States. International Journal of Pharmaceutical Sciences and Nanotechnology, 2013, 6, 2009-2013.	0.0	3
1142	Contemporary Trends in the Development of the Pharmaceutical Industry in the World. Studies of the Industrial Geography Commission of the Polish Geographical Society, 0, 25, 108-131.	0.1	8
1144	An Overview of Novel Drugs and New Chemical Entities in 2013. International Journal of Pharmaceutical Sciences and Nanotechnology, 2014, 7, 2505-2508.	0.0	0
1145	Oncogenic Signalling Networks and Polypharmacology as Paradigms to Cope with Cancer Heterogeneity. Current Proteomics, 2014, 11, 210-217.	0.1	1
1146	Techniques of Gastroretentive Floating Drug Delivery Advancement: A Review. Rajiv Gandhi University of Health Sciences Journal of Pharmaceutical Sciences, 2014, 4, 93-102.	0.1	0
1147	Development and Characterization of Oil Entrapped Stomach Site Specific 5-Fluorouracil Loaded Microcapsules. Rajiv Gandhi University of Health Sciences Journal of Pharmaceutical Sciences, 2014, 4, 110-119.	0.1	0
1148	Can Innovation Still Be the Main Growth Driver of the Pharmaceutical Industry?. Perspectives on Sustainable Growth, 2015, , 39-68.	0.3	1

#	Article	IF	Citations
1149	The Role of Neurohumoral Activation in Cardiac Fibrosis and Heart Failure. , 2015, , 347-381.		0
1150	Drug development. , 2015, , 395-400.		2
1151	Scientific Marketing in der PrÃklinik. , 2015, , 43-58.		0
1152	Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value. SSRN Electronic Journal, 0, , .	0.4	1
1153	Challenges in Obtaining Effective Access to Prescribed Drugs and Protection Against Financial Disruption: Addressing Barriers to Cancer Care in Ontario. SSRN Electronic Journal, 0, , .	0.4	0
1154	Competition and R&D Financing Decisions: Theory and Evidence from the Biopharmaceutical Industry. SSRN Electronic Journal, 0, , .	0.4	0
1155	Marketing im Gesundheitssektor. , 2015, , 173-197.		2
1156	Experimental and Clinical Approaches to Recovery after Stroke. European Neurological Review, 2015, 10, 65.	0.5	0
1158	Application of Quantitative Biomeasures in Early Drug Discovery. AAPS Advances in the Pharmaceutical Sciences Series, 2016, , 37-46.	0.2	0
1159	The Current System of Trade and Intellectual Property Rights. European Yearbook of International Economic Law, 2016, , 175-197.	0.1	0
1160	Growth and Returns to New Products and Pack Varieties: The Case of UK Pharmaceuticals. SSRN Electronic Journal, 0, , .	0.4	0
1161	Collaboration for success: the value of strategic col-laborations for precision medicine and biomarker discovery. Advances in Precision Medicine, 2016, 1, 25.	0.1	0
1162	Imaging Biomarkers in Clinical Trials. , 2017, , 295-306.		0
1163	Pricing for Survival in the Biopharma Industry: A Case Study of Acthar Gel and Questcor Pharmaceuticals. SSRN Electronic Journal, 0, , .	0.4	1
1164	Regulatory Growth Theory. SSRN Electronic Journal, 0, , .	0.4	0
1165	Translational Aspects in Drug Discovery. , 2017, , 495-529.		1
1166	A Call to Stop Treating Doctors Like Delinquent Adolescents and Medical Product Companies Like Criminal Enterprises. Philosophy and Medicine, 2017, , 65-91.	0.3	0
1168	III. Cost-effectiveness of Medical Oncology. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1125-1131.	0.0	0

#	Article	IF	Citations
1175	Measuring the Economic and Academic Impact of Philanthropic Funding: The Breast Cancer Research Foundation. SSRN Electronic Journal, 0, , .	0.4	0
1176	The Probabilistic Innovation Field of Scientific Enquiry. , 2019, , 1660-1677.		0
1177	Medicinal Plants as a Reservoir of New Structures for Anti-infective Compounds. , 2019, , 277-298.		1
1178	Paradigm Change in the History of the Pharmaceutical Industry. , 2019, , 239-263.		0
1181	In Dreams Begins Responsibility. , 2020, , 39-54.		0
1182	Legal Pluralism in Western Property Law. Ius Gentium, 2020, , 25-42.	0.1	0
1184	Future of Regulatory Safety Assessments. , 2020, , 1145-1168.		0
1186	Development and evaluation of next-generation cardiotoxicity assay based on embryonic stem cell-derived cardiomyocytes. BMB Reports, 2020, 53, 437-441.	1.1	2
1188	Harnessing the predictive power of preclinical models for oncology drug development. Nature Reviews Drug Discovery, 2022, 21, 99-114.	21.5	41
1189	Synthetic cells in biomedical applications. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, e1761.	3.3	30
1190	Challenges and Responses. , 2020, , 341-361.		0
1191	Web-based Tools for Drug Repurposing: Successful Examples of Collaborative Research. Current Medicinal Chemistry, 2020, 28, 181-195.	1.2	2
1192	TREAP: A New Topological Approach to Drug Target Inference. Biophysical Journal, 2020, 119, 2290-2298.	0.2	1
1193	Mining Natural Compounds to Target WNT Signaling: Land and Sea Tales. Handbook of Experimental Pharmacology, 2021, 269, 215-248.	0.9	6
1195	Alliance Management at Merck: Establishing an Operational 100-Day Plan for Alliance Launches and Management. , 2020, , 63-85.		0
1197	Structural and Biophysical Principles of Degrader Ternary Complexes. RSC Drug Discovery Series, 2020, , 14-54.	0.2	1
1199	Why an In Vivo Screening Platform Covering Broad Therapeutic Spectrum is an Ideal Tool for Drug Repositioning: Illustrated by Discovery of a Novel Class of Insulin Sensitizers. RSC Drug Discovery Series, 2020, , 217-232.	0.2	0
1201	The Utilization of Different Classifiers to Perform Drug Repositioning in Inclusion Body Myositis Supports the Concept of Biological Invariance. Lecture Notes in Computer Science, 2020, , 589-598.	1.0	1

#	Article	IF	Citations
1202	Artificial Intelligence and Drug Innovation: A Large Scale Examination of the Pharmaceutical Industry. SSRN Electronic Journal, 0, , .	0.4	3
1208	Using median survival in meta-analysis of experimental time-to-event data. Systematic Reviews, 2021, 10, 292.	2.5	2
1209	Experimental and Computational Approaches to Improve Binding Affinity in Chemical Biology and Drug Discovery. Current Topics in Medicinal Chemistry, 2020, 20, 1651-1660.	1.0	14
1211	Towards FAIR protocols and workflows: the OpenPREDICT use case. PeerJ Computer Science, 2020, 6, e281.	2.7	10
1213	Bygiene: The New Paradigm of Bidirectional Hygiene. Yale Journal of Biology and Medicine, 2015, 88, 359-65.	0.2	12
1214	Allosteric Modulation of G Protein-Coupled Receptors: An Emerging Approach of Drug Discovery. Austin Journal of Pharmacology and Therapeutics, 2014, 2, .	0.0	7
1216	Translating Stem Cell Biology Into Drug Discovery. Drug Target Review, 2016, 3, 34-38.	1.0	0
1217	Prediction of protein-ligand interactions from paired protein sequence motifs and ligand substructures. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing, 2018, 23, 20-31.	0.7	4
1218	Blockchain in the Biopharmaceutical Industry. Advances in Data Mining and Database Management Book Series, 2022, , 119-140.	0.4	1
1219	Challenges, Advances and Opportunities in Exploring Natural Products to Control Arboviral Disease Vectors. Frontiers in Chemistry, 2021, 9, 779049.	1.8	11
1221	Identification of ligand binding sites in intrinsically disordered proteins with a differential binding score. Scientific Reports, 2021, 11, 22583.	1.6	4
1222	Network medicine for disease module identification and drug repurposing with the NeDRex platform. Nature Communications, 2021, 12, 6848.	5.8	39
1223	Improving Translational Paradigms in Drug Discovery and Development. Current Protocols, 2021, 1, e273.	1.3	3
1224	To blind or not to blind first in human and exploratory clinical trials: Acceleration of development vs. risk of bias. Clinical and Translational Science, 2021, , .	1.5	3
1225	Natural ingredients from Chinese materia medica for pulmonary hypertension. Chinese Journal of Natural Medicines, 2021, 19, 801-814.	0.7	4
1226	Sharing R&D Risk in Healthcare via FDA Hedges. Review of Corporate Finance Studies, 2022, 11, 880-922.	1.4	5
1227	Innovation crisis in the pharmaceutical industry? A survey. SN Business & Economics, 2021, 1, 1.	0.6	11
1228	Maxsmi: Maximizing molecular property prediction performance with confidence estimation using SMILES augmentation and deep learning. Artificial Intelligence in the Life Sciences, 2021, 1, 100014.	1.6	6

#	Article	IF	Citations
1229	Antileishmanial Drug Discovery and Development: Time to Reset the Model?. Microorganisms, 2021, 9, 2500.	1.6	32
1230	Public consultation in the evaluation of animal research protocols. PLoS ONE, 2021, 16, e0260114.	1.1	2
1233	Peptides and Peptidomimetics as Foundations for Drug Discovery. , 2021, , 1219-1226.		0
1235	Smart design approaches for orally administered lipophilic prodrugs to promote lymphatic transport. Journal of Controlled Release, 2022, 341, 676-701.	4.8	16
1236	Transcription Factor Activation Profiles (TFAP) identify compounds promoting differentiation of Acute Myeloid Leukemia cell lines. Cell Death Discovery, 2022, 8, 16.	2.0	0
1237	Emerging targetome and signalome landscape of gut microbial metabolites. Cell Metabolism, 2022, 34, 35-58.	7.2	30
1238	Immunoinformatics: Pushing the boundaries of immunology research and medicine. ImmunoInformatics, 2022, 5, 100007.	1.2	2
1239	DeepMGT-DTI: Transformer network incorporating multilayer graph information for Drugâ€“Target interaction prediction. Computers in Biology and Medicine, 2022, 142, 105214.	3.9	33
1240	Supervised learning with word embeddings derived from PubMed captures latent knowledge about protein kinases and cancer. NAR Genomics and Bioinformatics, 2021, 3, lqab113.	1.5	4
1241	Characterization of the Microflow Through 3D Synthetic Niche Microenvironments Hosted in a Millifluidic Bioreactor. Frontiers in Bioengineering and Biotechnology, 2021, 9, 799594.	2.0	0
1242	Computational Genomics in the Era of Precision Medicine: Applications to Variant Analysis and Gene Therapy. Journal of Personalized Medicine, 2022, 12, 175.	1.1	4
1243	A community challenge for a pancancer drug mechanism of action inference from perturbational profile data. Cell Reports Medicine, 2022, 3, 100492.	3.3	33
1245	From organ-on-a-chip towards body-on-a-chip. Biocell, 2022, 46, 1177-1180.	0.4	0
1246	Pharmaceutical spending and early-stage innovation in EU countries. Industry and Innovation, 2022, 29, 1141-1170.	1.7	2
1247	Dose Number as a Tool to Guide Lead Optimization for Orally Bioavailable Compounds in Drug Discovery. Journal of Medicinal Chemistry, 2022, 65, 1685-1694.	2.9	7
1248	Mechanistic Basis for the Role of Phytochemicals in Inflammation-Associated Chronic Diseases. Molecules, 2022, 27, 781.	1.7	14
1249	Assessing the impact of automation in pharmaceutical quality control labs using a digital twin. Journal of Manufacturing Systems, 2022, 62, 270-285.	7.6	7
1250	Introduction and Historical Overview of Drug Repurposing Opportunities. RSC Drug Discovery Series, 2022, , 1-13.	0.2	4

#	Article	IF	Citations
1251	A reconsideration of university gap funds for promoting biomedical entrepreneurship. Journal of Clinical and Translational Science, 2022, 6, .	0.3	1
1252	Dissecting the Mechanism of Action of Spiperoneâ€"A Candidate for Drug Repurposing for Colorectal Cancer. Cancers, 2022, 14, 776.	1.7	3
1253	Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends in Pharmacological Sciences, 2022, 43, 136-150.	4.0	294
1254	Enhancing organisational innovation capability â€“ A practice-oriented insight for pharmaceutical companies. Technovation, 2022, 115, 102461.	4.2	9
1256	Are There Hidden Genes in DNA/RNA Vaccines?. Frontiers in Immunology, 2022, 13, 801915.	2.2	9
1257	Organ-on-a-chip platforms as novel advancements for studying heterogeneity, metastasis, and drug efficacy in breast cancer. , 2022, 237, 108156.		12
1258	Machine learning and deep learning in data-driven decision making of drug discovery and challenges in high-quality data acquisition in theÂpharmaceutical industry. Future Medicinal Chemistry, 2022, 14, 245-270.	1.1	14
1259	Profitability and drug discovery. Industrial and Corporate Change, 2022, 31, 891-904.	1.7	4
1260	The Incipient Role of Computational Intelligence in Oncology: Drug Designing, Discovery, and Development. Studies in Computational Intelligence, 2022, , 369-384.	0.7	6
1262	A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer. ELife, 2022, 11, .	2.8	47
1263	Recycled Translation: Repurposing Drugs for Stroke. Translational Stroke Research, 2022, 13, 866-880.	2.3	5
1264	Drug Repositioning: Exploring New Indications for Existing Drug-Disease Relationships. Endocrinology and Metabolism, 2022, 37, 62-64.	1.3	2
1265	CRISPR in cancer biology and therapy. Nature Reviews Cancer, 2022, 22, 259-279.	12.8	157
1266	Machine Learning guided early drug discovery of small molecules. Drug Discovery Today, 2022, 27, 2209-2215.	3.2	22
1268	The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets. Npj Genomic Medicine, 2022, 7, 25.	1.7	8
1269	SSGraphCPI: A Novel Model for Predicting Compound-Protein Interactions Based on Deep Learning. International Journal of Molecular Sciences, 2022, 23, 3780.	1.8	12
1270	The Beatles in life sciences: Facts and fictions. Biochemistry and Molecular Biology Education, 2022, 50, 334-344.	0.5	0
1271	Identification of Chemicalâ€"Disease Associations Through Integration of Molecular Fingerprint, Gene Ontology and Pathway Information. Interdisciplinary Sciences, Computational Life Sciences, 2022, , 1.	2.2	0

#	Article	IF	Citations
1272	In Vitro Cancer Models: A Closer Look at Limitations on Translation. Bioengineering, 2022, 9, 166.	1.6	11
1273	Supporting Innovation in Early-Stage Pharmaceutical Development Decisions. Decision Analysis, 2022, 19, 337-353.	1.2	1
1274	Inhibition of PDK3 by artemisinin, a repurposed antimalarial drug in cancer therapy. Journal of Molecular Liquids, 2022, 355, 118928.	2.3	16
1275	Why medicines work. , 2022, 238, 108175.		1
1277	The importance of drug target selection capability for new drug innovation: definition, fostering process, and interaction with organizational management. Prometheus, 2020, 36, .	0.2	0
1278	Applications of Quantitative System Pharmacology Modeling to Model-Informed Drug Development. Methods in Molecular Biology, 2022, 2486, 71-86.	0.4	0
1279	2021 in review: FDA approvals of new medicines. Drug Discovery Today, 2022, 27, 2057-2064.	3.2	9
1280	Characterization of Altered Molecular Pathways in the Entorhinal Cortex of Alzheimerâ€™s Disease Patients and In Silico Prediction of Potential Repurposable Drugs. Genes, 2022, 13, 703.	1.0	3
1282	Double Repositioning: Veterinary Antiparasitic to Human Anticancer. International Journal of Molecular Sciences, 2022, 23, 4315.	1.8	5
1283	Inequities in cancer drug development in terms of unmet medical need. Social Science and Medicine, 2022, 302, 114953.	1.8	2
1284	Combinations of Drug Candidate Properties Affecting Development Success and Discontinuation for 5 Diseases: Lymphoma, Nonâ€“Small Cell Lung Cancer, Arthritis, Depression, and Alzheimer Disease. Journal of Clinical Pharmacology, 2022, 62, 1247-1256.	1.0	0
1285	Impact and Evolution of Biophysics in Medicinal Chemistry. RSC Drug Discovery Series, 2017, , 1-22.	0.2	0
1291	Medicine adaptive pathways to patients (MAPPs): using regulatory innovation to defeat Eroom's law. Chinese Clinical Oncology, 2014, 3, 21.	0.4	7
1292	An Orchestration Framework for Digital Innovation: Lessons From the Healthcare Industry. IEEE Transactions on Engineering Management, 2023, 70, 2465-2479.	2.4	4
1293	The Patient-Derived Cancer Organoids: Promises and Challenges as Platforms for Cancer Discovery. Cancers, 2022, 14, 2144.	1.7	5
1294	Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19. Frontiers in Drug Discovery, 2022, 2, .	1.1	5
1295	Metabolically driven maturation of human-induced-pluripotent-stem-cell-derived cardiac microtissues on microfluidic chips. Nature Biomedical Engineering, 2022, 6, 372-388.	11.6	42
1296	A publicâ€“private collaboration model for clinical innovation. Clinical and Translational Science, 2022, 15, 1581-1591.	1.5	1

#	Article	IF	Citations
1297	Recentering neuroscience on behavior: The interface between brain and environment is a privileged level of control of neural activity. Neuroscience and Biobehavioral Reviews, 2022, 138, 104678.	2.9	10
1298	Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021. Clinical Pharmacology and Therapeutics, 2022, 112, 817-823.	2.3	3
1300	Drug repositioning of polaprezinc for bone fracture healing. Communications Biology, 2022, 5, 462.	2.0	5
1301	Antibiotic resistant bacteria: current situation and treatment options to accelerate the development of a new antimicrobial arsenal. Expert Review of Anti-Infective Therapy, 2022, 20, 1095-1108.	2.0	24
1302	Challenges with Defining Pharmaceutical Markets and Potential Remedies to Screen for Industry Consolidation. Journal of Health Politics, Policy and Law, 2022, , .	0.9	0
1303	Identifying and Mitigating Potential Biases in Predicting Drug Approvals. Drug Safety, 2022, 45, 521-533.	1.4	2
1307	Inhibition of autolysosomes by repurposing drugs as a promising therapeutic strategy for the treatment of cancers. International Journal of Transgender Health, 2022, 15, 568-601.	1.1	2
1308	Drug repositioning for cancer in the era of AI, big omics, and real-world data. Critical Reviews in Oncology/Hematology, 2022, 175, 103730.	2.0	10
1309	Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models. Journal of Visualized Experiments, 2022, , .	0.2	0
1310	Delegated Concept Testing in New Product Development. Operations Research, 2022, 70, 2732-2748.	1.2	3
1311	Recent Developments on Ionic Liquids and Deep Eutectic Solvents for Drug Delivery Applications. Pharmaceutical Research, 2022, 39, 2367-2377.	1.7	25
1312	Computational Analysis of Pathogenetic Pathways in Alzheimerâ€™s Disease and Prediction of Potential Therapeutic Drugs. Brain Sciences, 2022, 12, 827.	1.1	3
1313	Robust, Automated Analysis of Electrophysiology in Induced Pluripotent Stem Cell-Derived Micro-Heart Muscle for Drug Toxicity. Tissue Engineering - Part C: Methods, 2022, 28, 457-468.	1.1	6
1314	IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation. Bosnian Journal of Basic Medical Sciences, 0, , .	0.6	4
1315	From Traditional Ethnopharmacology to Modern Natural Drug Discovery: A Methodology Discussion and Specific Examples. Molecules, 2022, 27, 4060.	1.7	24
1316	Repurposing Drugs via Network Analysis: Opportunities for Psychiatric Disorders. Pharmaceutics, 2022, 14, 1464.	2.0	8
1317	BioLumin: An Immersive Mixed Reality Experience for Interactive Microscopic Visualization and Biomedical Research Annotation. ACM Transactions on Computing for Healthcare, 2022, 3, 1-28.	3.3	0
1321	Lifecycle management of orphan drugs approved in Japan. Orphanet Journal of Rare Diseases, 2022, 17, .	1.2	2

#	Article	IF	Citations
1322	Advanced human liver models for the assessment of drug-induced liver injury. Organoid, 0, 2, e17.	0.0	0
1323	3-Dimensional mesothelioma spheroids provide closer to natural pathophysiological tumor microenvironment for drug response studies. Frontiers in Oncology, 0, 12, .	1.3	6
1324	Application of Machine Learning Technology in the Prediction of ADME- Related Pharmacokinetic Parameters. Current Medicinal Chemistry, 2023, 30, 1945-1962.	1.2	2
1327	A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automated Caenorhabditis elegans screening platform. Heliyon, 2022, 8, e10108.	1.4	5
1328	Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?. Drug Discovery Today, 2022, 27, 103333.	3.2	1
1329	Regulated cell death (RCD) in cancer: key pathways and targeted therapies. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	169
1330	MD analysis of heat transfer of carbon nanotube flow on nanopumping process to improve the hydrodynamic and thermal performances. Engineering Analysis With Boundary Elements, 2022, 144, 507-517.	2.0	2
1331	General Strategies for Rational Design and Discovery of Multitarget Drugs. , 2022, , 677-736.		0
1332	Challenges with Defining Pharmaceutical Markets and Potential Remedies to Screen for Industry Consolidation. SSRN Electronic Journal, 0, , .	0.4	0
1333	Platform Trial Designs. , 2022, , 1455-1485.		0
1335	Key Factors to Improve Pharmaceutical Industry's R&D Productivity: A Case Study of Iranian Pharmaceutical Holding. Medical Journal of the Islamic Republic of Iran, 0, , .	0.9	0
1336	Effect of External Innovation on Advanced Pharmaceutical R&D: The Case of Monoclonal Antibody Drug Development. , 2022, , .		0
1338	Deconstructing Markush: Improving the R&D Efficiency Using Library Selection in Early Drug Discovery. Pharmaceuticals, 2022, 15, 1159.	1.7	1
1339	On drug discovery against infectious diseases and academic medicinal chemistry contributions. Beilstein Journal of Organic Chemistry, 0, 18, 1355-1378.	1.3	0
1340	Identification of a potential inhibitor for New Delhi metallo-Î²-lactamase 1 (NDM-1) from FDA approved chemical library- a drug repurposing approach to combat carbapenem resistance. Journal of Biomolecular Structure and Dynamics, 2023, 41, 7700-7711.	2.0	1
1341	High-throughput mechanistic screening of non-equilibrium inhibitors by a fully automated data analysis pipeline in early drug-discovery. SLAS Discovery, 2022, 27, 460-470.	1.4	1
1342	Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). , 2022, 10, e005413.		6
1343	Measurement of oxygen consumption rates of human renal proximal tubule cells in an array of organ-on-chip devices to monitor drug-induced metabolic shifts. Microsystems and Nanoengineering, 2022, 8, .	3.4	5

#	Article	IF	Citations
1344	Proposal to Consider Chemical/Physical Microenvironment as a New Therapeutic Off-Target Approach. Pharmaceutics, 2022, 14, 2084.	2.0	4
1345	New lead compounds identification against KRas mediated cancers through pharmacophore-based virtual screening and inÂvitro assays. Journal of Biomolecular Structure and Dynamics, 2023, 41, 8053-8067.	2.0	6
1346	Predictive validity in drug discovery: what it is, why it matters and how to improve it. Nature Reviews Drug Discovery, 2022, 21, 915-931.	21.5	28
1347	MultiscaleDTA: A multiscale-based method with a self-attention mechanism for drug-target binding affinity prediction. Methods, 2022, 207, 103-109.	1.9	4
1349	Harnessing AI and Genomics to Accelerate Drug Discovery. Future of Business and Finance, 2022, , 89-106.	0.3	1
1350	Adera2.0: A Drug Repurposing Workflow for Neuroimmunological Investigations Using Neural Networks. Molecules, 2022, 27, 6453.	1.7	2
1352	Building a brighter future for Africa with the African Light Source. Nature Reviews Physics, 2023, 5, 74-75.	11.9	3
1353	Fluvoxamine prompts the antitumor immune effect via inhibiting the PDâ€L1 expression on miceâ€burdened colon tumor. Cell Biology International, 2023, 47, 439-450.	1.4	4
1354	Addressing Noise and Estimating Uncertainty in Biomedical Data through the Exploration of Chemical Space. International Journal of Molecular Sciences, 2022, 23, 12975.	1.8	0
1355	Monitoring of Drug Release via Intra Body Communication with an Edible Pill. Advanced Materials Technologies, 2023, 8, .	3.0	9
1356	Bioengineered Pancreasâ€“Liver Crosstalk in a Microfluidic Coculture Chip Identifies Human Metabolic Response Signatures in Prediabetic Hyperglycemia. Advanced Science, 2022, 9, .	5.6	11
1358	Exceptional Repositioning of Dog Dewormer: Fenbendazole Fever. Current Issues in Molecular Biology, 2022, 44, 4977-4986.	1.0	3
1359	The gap between development and manufacturing in gene therapy: strategic options for overcoming traps. Drug Discovery Today, 2022, , 103429.	3.2	1
1360	Financing Biomedical Innovation. Annual Review of Financial Economics, 2022, 14, 231-270.	2.5	14
1361	Possibility Extent and Possible Alternatives Preorder Type-2 Fuzzy Analytical Hierarchy Process (PE&PAP-AHP) to improve pharmaceutical R&D productivity. Applied Soft Computing Journal, 2022, 131, 109770.	4.1	0
1362	What is the importance of difference in LCM strategy in drug development? â€“ Learnings from Keytruda and Opdivo. Drug Discovery Today, 2022, 27, 103390.	3.2	0
1363	Radiolabelling small and biomolecules for tracking and monitoring. RSC Advances, 2022, 12, 32383-32400.	1.7	11
1364	Dâ€™une pandÃ©mie Ã lâ€™autre, raretÃ© artificielle et rente sous brevet de mÃ©dicament. Ã‰conomie Et Institutions, 2022, , .	0.1	0

#	Article	IF	Citations
1365	Fabrication of a Polymeric Inhibitor of Proximal Metabolic Enzymes in Hypoxia for Synergistic Inhibition of Cancer Cell Proliferation, Survival, and Migration. ACS Applied Materials & Interfaces, 2022, 14, 51790-51797.	4.0	1
1366	Partnership Models forÂR &D inÂtheÂPharmaceutical Industry. SpringerBriefs in Economics, 2023, , 29-48.	0.1	1
1367	Identification of potential targets of cinnamon for treatment against Alzheimerâ€™s disease-related GABAergic synaptic dysfunction using network pharmacology. Scientific Reports, 2022, 12, .	1.6	6
1368	Learning to discover medicines. International Journal of Data Science and Analytics, 2023, 16, 301-316.	2.4	0
1369	Improving combination drug trials using â€˜definitive screening designsâ€™. Nature Biotechnology, 0, , .	9.4	0
1370	Cell morphology-guided de novo hit design by conditioning GANs on phenotypic image features. , 2023, 2, 91-102.		4
1371	Optimizing drug discovery: An opportunity and application with reverse translational research. Health Sciences Review, 2023, 6, 100074.	0.6	0
1372	CPGL: Prediction of Compound-Protein Interaction by Integrating Graph Attention Network With Long Short-Term Memory Neural Network. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2022, , 1-8.	1.9	0
1373	Hibernation or Transformation? Challenges in Cardiovascular Drug Development. Frontiers in Cardiovascular Drug Discovery, 2022, , 102-140.	0.0	0
1374	Comprehensive bioinformatics analysis reveals biomarkers of DNA methylation-related genes in varicose veins. Frontiers in Genetics, 0, 13, .	1.1	1
1375	Mebendazole Impedes the Proliferation and Migration of Pancreatic Cancer Cells through SK1 Inhibition Dependent Pathway. Molecules, 2022, 27, 8127.	1.7	2
1376	3D organ-on-a-chip: The convergence of microphysiological systems and organoids. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	16
1377	Critical design parameters to develop biomimetic organ-on-a-chip models for the evaluation of the safety and efficacy of nanoparticles. Expert Opinion on Drug Delivery, 2023, 20, 13-30.	2.4	3
1378	Organ-on-a-chip: Its use in cardiovascular research. Clinical Hemorheology and Microcirculation, 2023, 83, 315-339.	0.9	2
1379	Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology. Communications Medicine, 2022, 2, .	1.9	61
1380	Outsourcing of research and development and efficiency: a DEA non-parametric analysis of the contract research organisations industry. Economic Research-Ekonomska Istrazivanja, 2023, 36, .	2.6	1
1381	Pharmaceutical innovation and access to financial markets. PLoS ONE, 2022, 17, e0278875.	1.1	1
1382	Prospectively shared control data across concurrent randomised clinical trials. European Journal of Cancer, 2023, 181, 18-20.	1.3	1

#	Article	IF	Citations
1383	<scp>QuoteTarget</scp>: A sequenceâ€based transformer protein language model to identify potentially druggable protein targets. Protein Science, 2023, 32, .	3.1	5
1384	Past and current drug repurposing clinical trials to treat cognition in methamphetamine use: a scoping review of pharmacotherapy candidates. Addiction Neuroscience, 2023, 5, 100064.	0.4	2
1385	Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers. International Journal of Molecular Sciences, 2023, 24, 1334.	1.8	17
1386	The drug treatment deadlock in psychiatry and the route forward. World Psychiatry, 2023, 22, 2-3.	4.8	3
1387	Deciphering Nonbioavailable Substructures Improves the Bioavailability of Antidepressants by Serotonin Transporter. Journal of Medicinal Chemistry, 2023, 66, 371-383.	2.9	2
1388	Recent trends in interorganizational deal networks in pharmaceutical and biotechnology industries. Drug Discovery Today, 2023, 28, 103483.	3.2	2
1389	Reverse Translational Approach in Repurposing of Drugs for Anticancer Therapy. , 2023, , 299-328.		0
1390	The rocky road to translational science: An analysis of Clinical and Translational Science Awards. Research Evaluation, 0, , .	1.3	0
1391	Fast Methods for Drug Approval: Research Perspectives for Pandemic Preparedness. International Journal of Environmental Research and Public Health, 2023, 20, 2404.	1.2	0
1392	Drug Repurposing: An Advance Way to Traditional Drug Discovery. , 2023, , 1-25.		0
1393	Valuing Pharmaceutical Drug Innovations: An Event Study Approach. SSRN Electronic Journal, 0, , .	0.4	0
1394	Drug discovery: Standing on the shoulders of giants. , 2023, , 207-338.		0
1395	RNA sequencing least shrew (Cryptotis parva) brainstem and gut transcripts following administration of a selective substance P neurokinin NK1 receptor agonist and antagonist expands genomics resources for emesis research. Frontiers in Genetics, 0, 14, .	1.1	0
1396	From basic sciences and engineering to epileptology: A translational approach. Epilepsia, 2023, 64, .	2.6	0
1397	Review on 505(b)(2) drug products approved by USFDA from 2010 to 2020 emphasizing intellectual property and regulatory considerations for reformulations and new combinations. Journal of Pharmaceutical Sciences, 2023, , .	1.6	0
1399	Novel hydrogels: are they poised to transform 3D cell-based assay systems in early drug discovery?. Expert Opinion on Drug Discovery, 2023, 18, 335-346.	2.5	1
1400	Unveiling New Druggable Pockets in Influenza Non-Structural Protein 1: NS1â€“Host Interactions as Antiviral Targets for Flu. International Journal of Molecular Sciences, 2023, 24, 2977.	1.8	0
1401	Cell-free Biosynthesis of Peptidomimetics. Biotechnology and Bioprocess Engineering, 2023, 28, 905-921.	1.4	4

#	Article	IF	Citations
1402	Quantitative comparison of protein-protein interaction interface using physicochemical feature-based descriptors of surface patches. Frontiers in Molecular Biosciences, 0, 10, .	1.6	1
1403	National Institutes of Health research project grant inflation 1998 to 2021. ELife, 0, 12, .	2.8	1
1404	Screening a small hydrazide-hydrazone combinatorial library for targeting the STAT3 in monocyte-macrophages with insulated reporter transposons. Medicinal Chemistry Research, 2023, 32, 682-693.	1.1	1
1405	Perspective on the challenges and opportunities of accelerating drug discovery with artificial intelligence. Frontiers in Bioinformatics, 0, 3, .	1.0	3
1406	Can nanomedicine improve the effectiveness of drugs used to treat neglected tropical diseases?. Nanomedicine, 0, , .	1.7	1
1407	Progress and Understandings in the Pharmacological Repositioning Scenario. European Journal of Medical and Health Sciences, 2023, 5, 28-31.	0.1	0
1408	Financial intermediation and the funding of biomedical innovation: A review. Journal of Financial Intermediation, 2023, 54, 101028.	1.4	5
1409	Molecular-evaluated and explainable drug repurposing for COVID-19 using ensemble knowledge graph embedding. Scientific Reports, 2023, 13, .	1.6	4
1411	Drug discovery: Chaos can be your friend or your enemy. , 2023, , 417-511.		2
1412	Backgrounderâ€"Part 1. , 2023, , 3-26.		0
1413	Research and discovery: Essential partners but just a start. , 2023, , 513-527.		0
1414	Contributions of the Department of Defense Congressionally Directed Medical Research Programs to Advances in Cancer Therapeutics. Military Medicine, 2023, 188, 190-194.	0.4	1
1415	A Systematic Review of Deep Learning Methodologies Used in the Drug Discovery Process with Emphasis on In Vivo Validation. International Journal of Molecular Sciences, 2023, 24, 6573.	1.8	4
1416	Chemical representation learning for toxicity prediction. , 2023, 2, 674-691.		3
1417	Organ-on-a-Chip for Drug Screening: A Bright Future for Sustainability? A Critical Review. ACS Biomaterials Science and Engineering, 2023, 9, 2220-2234.	2.6	2
1418	A Systematic Review of Molecular Pathway Analysis of Drugs for Potential Use in Liver Cancer Treatment. , 2023, 2, 210-231.		0
1420	Key aspects for conception and construction of co-culture models of tumor-stroma interactions. Frontiers in Bioengineering and Biotechnology, 0, 11, .	2.0	2
1421	Is the â€œsailing-ship effectâ€•misnamed? A statistical inquiry of the case sail vs steam in maritime transportation. Industrial and Corporate Change, 0, , .	1.7	0

#	Article	IF	Citations
1422	Knowledge Mapping of Drug Repositioningâ€™s Theme and Development. Drug Design, Development and Therapy, 0, Volume 17, 1157-1174.	2.0	1
1425	Artificial Intelligence Methods in Marine Biotechnology. , 2023, , 339-354.		0
1429	A MIST conception: what has been learned from twenty years of human metabolite safety assessment?. Medicinal Chemistry Research, 2023, 32, 1933-1949.	1.1	3
1437	Leveraging ADME/PK information to enable knowledge-driven decisions in drug discovery and development. , 2023, , 9-24.		0
1438	Systems biology and data science in research and translational medicine. , 2023, , 25-39.		0
1444	Advanced Technologies in Health and Neurodegenerative Diseases. , 2023, , 629-653.		0
1448	Artificial neural networkâ€“based inference of drugâ€“target interactions. , 2023, , 35-62.		0
1449	An Efficient Drug Design Method Based on Drug-Target Affinity. Lecture Notes in Computer Science, 2023, , 764-775.	1.0	0
1454	Chemoresistance Mechanisms in Non-Small Cell Lung Cancerâ€”Opportunities for Drug Repurposing. Applied Biochemistry and Biotechnology, 0, , .	1.4	0
1459	RxRx1: A Dataset for Evaluating Experimental Batch Correction Methods. , 2023, , .		8
1460	Drug Approval Prediction using Patents. , 2023, , .		0
1463	In Silico Clinical Trials: Is It Possible?. Methods in Molecular Biology, 2024, , 51-99.	0.4	0
1481	Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy. British Journal of Cancer, 2024, 130, 703-715.	2.9	4
1488	Semiconductorsâ€™ miniaturization through time: from Mooreâ€™s law to Eroomâ€™s Law?. , 2023, , .		0
1492	Predictive Enrichment: Einsatz in klinischen Studien. , 2023, , 77-79.		0
1497	A network-based bioinformatic analysis for identifying potential repurposable active molecules in different types of human cancers. , 2023, , .		0
1498	Commercial achievements resulting from multi-organ-on-a-chip applications. , 2024, , 309-342.		0
1501	WANTED DEAD OR ALIVE: New Thinking to Incentivize Drug Development. Pharmaceutical Research, 2024, 41, 199-202.	1.7	0

#	Article	IF	Citations
1503	Use of Bioinformatics in High-Throughput Drug Screening. , 2024, , 249-260.		0
1514	Future of Regulatory Safety Assessment. , 2023, , 1-26.		0
1517	The Process of Drug Development from Natural Sources. , 2024, , 17-42.		0